

## INDEX

Note: Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.

- 4S (simvastatin) trial, 316t
- A1C. See *Glycosylated hemoglobin (A1C)*.
- A Diabetes Outcome Progression Trial. See *ADOPT*.
- Abdominal pain, in diabetic ketoacidosis, 288t. See also *Gastrointestinal symptoms*.
- Acanthosis nigricans  
diabetes secondary to, 30t  
in dysmetabolic syndrome X, 45t
- Acarbose (Precose), 76t, 143-144  
action mechanism, 142, 143  
combination therapy, 143, 151  
dosing, 76t, 144, 145t  
glycemic control with, 143  
hypoglycemia, safety for, 143-144  
PPG levels and, 143  
prescribing considerations, 144, 145t  
side effects, 143-144  
in Stop-NIDDM, 344t, 347
- ACCORD trial, 69-70, 71, 71, 72, 113-114
- Accu-Chek monitoring systems, 266t
- ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.
- Acetaminophen, for painful diabetic neuropathies, 329
- Acetohexamide (Dymelor), 77t, 146
- Acetone breath, in diabetic ketoacidosis, 288t
- Acidosis. See also *Diabetic ketoacidosis (DKA)*.  
in diabetic ketoacidosis, 287-288  
lactic, MET therapy and, 81-82
- Acquired factors in type 2 diabetes, 22, 23, 24-25
- Acromegaly, diabetes secondary to, 30t
- ACT-NOW (Actos Now for Prevention of Diabetes trial), 350
- Action to Control Cardiovascular Risk in Diabetes. See *ACCORD trial*.
- Actoplus Met (pioglitazone/metformin), 78t, 99. See also *Metformin*;  
*Pioglitazone*.  
glycemic control with, 99, 100t-101t  
prescribing considerations, 110
- Actos Now for Prevention of Diabetes (ACT-NOW) trial, 350
- Actos. See *Pioglitazone*.
- Acupuncture, for painful diabetic neuropathies, 328, 329
- Acute complications. See *Complications of diabetes, acute*.
- ADA. See *American Diabetes Association*.
- Adolescents, type 2 diabetes in, 35
- ADOPT (A Diabetes Outcome Progression Trial), 85-86, 86, 114
- Advance Intuition monitoring system, 266t
- ADVANCE trial, 69-70, 71-72
- Advocate Meter, 266t
- Advocate Redi-Code, 267t
- Afrezza, 170
- African Americans. See also *Race/ethnicity*.  
incidence of diabetes in, 18  
prevalence of diabetes in, 13, 15, 32, 37
- Age  
incidence of diabetes and, 16-17, 17, 18  
of onset  
late-onset type 1 diabetes (LADA), 189, 286, 290  
maturity-onset diabetes of the young, 35  
type 1 diabetes, 29, 30t  
type 2 diabetes, 30t, 32, 35  
prevalence of diabetes and, 13, 14  
as risk factor for CHD, 41  
as risk factor for diabetes, 13, 22, 23, 34, 38  
screening and, 352  
undiagnosed diabetes and, 14
- Alanine aminotransferase (ALT)  
in diabetic ketoacidosis, 289t  
rosiglitazone and, 348  
TZD therapy and, 111
- Alaskan natives, prevalence of diabetes in, 13, 15
- Alcohol use/intake, 52t, 57  
glycemic testing, false highs with, 260  
SFUs and, 57, 146
- Aldosteronism, diabetes secondary to, 30t
- Algorithm  
for insulin therapy, 178, 179  
for treatment, 251-253, 254-255
- Allergy to insulin, 171
- ALLHAT, 351t
- $\alpha$ -Blockers, 306t, 307t, 309  
in treatment of diabetic nephropathy, 326
- $\alpha$ -Cell hormone. See *Glucagon*.
- Alpha-glucosidase inhibitors, 76t, 142-145. See also *Acarbose*; *Miglitol*.  
action mechanism, 142  
in algorithm for treatment, 254  
combination therapy, 81, 143, 254  
dosing, 76t, 144, 145t  
side effects, 143-144
- ALT. See *Alanine aminotransferase*.
- Amaryl. See *Glimepiride*.
- American Association of Clinical Endocrinologists (AAACE)  
dysmetabolic syndrome criteria, 45, 45t  
management goals and targets, 253  
PPG/glycemic control goals, 65, 66t, 253
- American Association of Diabetes Educators (AADE), 355
- American Association of Kidney Patients, Inc. (AAKP), 355
- American College of Cardiology, sildenafil recommendations, 334-335
- American Diabetes Association (ADA), 355-356  
ADA/AHA consensus conference, 112  
ADA/EASD consensus statement, 75, 253, 265  
criteria for diabetes diagnosis, 38t  
on dyslipidemia treatment priorities, 314, 315t  
glycemic control targets/goals, 41, 66t, 253  
management goals for diabetes, 253

- American Diabetes Association (ADA) (*continued*)  
 on screening for diabetes, 352  
 on self-monitoring of blood glucose, 265
- American Dietetic Association, 356
- American Heart Association, 357
- American Indians  
 incidence of diabetes in, 18  
 Indian Health Services (IHS), 357-358  
 prevalence of diabetes in, 13, 15, 32  
 risk of diabetes in, 37
- Amitriptyline, for painful diabetic neuropathies, 328, 329
- Amoxicillin trihydrate, 331
- Amputation, 336  
 end points in PROactive study, 106-107, 108  
 end points in Steno-2 Trial, 70  
 foot care for prevention of, 336-337, 338t
- Amylin, 237-240  
 action mechanisms, 238-240, 240  
 analogue (pramlintide). See *Pramlintide therapy*.  
 cosecretion with insulin, 238, 239  
 deficiency in diabetes, 238, 239, 241  
 GLP-1 and, 199
- Amyotrophy, diabetic, 327t, 330
- Angiotensin-converting enzyme (ACE) inhibitors, 305-308  
 as initial therapy for hypertension, 44-45, 308  
 as initial therapy for microalbuminuria, 45, 308  
 potassium and, 56-57, 308  
 potential benefits of, 307t  
 potential complications of, 306t  
 in treatment of diabetic nephropathy, 324, 325, 326  
 in treatment of metabolic syndrome, 44-45  
 trials of, 350, 351t  
 Steno-2 Trial, 69  
 UKPDS, 308
- Angiotensin II receptor blockers (ARBs), 305, 309  
 as initial therapy for hypertension, 44-45  
 as initial therapy for microalbuminuria, 45  
 potential benefits of, 307t  
 potential complications of, 306t  
 in treatment of diabetic nephropathy, 324, 325, 326  
 in treatment of metabolic syndrome, 44-45  
 trials of, 350, 351t  
 NAVIGATOR trial, 350  
 Steno-2 Trial, 69
- Anorexia  
 in diabetic ketoacidosis, 288t  
 in diabetic neuropathy, 328  
 metformin and, 81  
 pramlintide and, 241
- Antibiotics, 300-301t, 331
- Antibodies  
 to GAD, 36, 170, 189  
 to insulin, 171, 178
- Antifungal therapy, 300t
- Antihypertensive drugs, 21t, 305-310, 350, 351t. See also *specific agents*.  
 clinical trials involving, 351t  
 potential benefits of, 307t, 350, 351t  
 potential complications of, 306t  
 secondary diabetes associated with, 30t  
 side effects with, 305, 306t  
 in treatment of diabetic nephropathy, 324, 325, 326
- Anti-inflammatory agents, for diabetic neuropathies, 327
- Anti-inflammatory effects, of rosiglitazone, 95
- Antioxidant supplements, 52t, 57, 325
- Apidra (glulisine), 170, 190  
 regimens for, 177t  
 time course of action, 172-173, 174t, 176
- Appetite  
 GLP-1 reduction of, 200-201  
 pramlintide reduction of, 239, 240
- ARBs. See *Angiotensin II receptor blockers (ARBs)*.
- Argon laser photocoagulation, 322-323
- Asian/Asian-American patients, 352. See also *Race/ethnicity*.
- Aspart (Novolog), 170, 190. See also *Novolog*; *Novolog Mix*.  
 time course of action, 172-173, 174t
- Aspirin  
 glycemic testing, false highs with, 260  
 in Steno-2 Trial, 69  
 in treatment of metabolic syndrome, 45  
 in treatment of painful diabetic neuropathies, 328, 329
- Assessment of treatment regimen, 257-284  
 fructosamine measurement, 260-261, 261  
 glycated hemoglobin measurement, 259-260  
 key parameters, 257  
 metabolic goals, 258t  
 other glycated proteins, 260-261, 261  
 plasma glucose concentrations, 257-259  
 self-monitoring of blood glucose, 261-283, 266t-272t. See also  
*Self-monitoring of blood glucose (SMBG)*.
- Asymptomatic diabetes, 32-33, 37
- Atenolol, in UKPDS, 308, 309
- Atherosclerosis  
 antioxidant supplements and, 57  
 dyslipidemia and, 310  
 type 2 diabetes and, 63
- Atorvastatin, 315, 316t
- Autoimmunity, 29, 170
- Avandamet (rosiglitazone/metformin), 78t, 89-91  
 dosage, 78t, 96  
 as first-line therapy, 89, 96  
 glycemic control with, 89-91, 90t  
 prescribing considerations, 96  
 as second-line therapy, 89, 91, 92t, 96
- Avandaryl (rosiglitazone/glimepiride), 78t, 91-93, 95  
 cardiovascular risk and, 95  
 dosage, 78t, 96  
 glycemic control with, 91, 94t  
 prescribing considerations, 96-97

Avandia. See *Rosiglitazone*.

B-type natriuretic peptide (BNP), 113

Bacteriuria, 300t

$\beta$ -Blockers, 306t, 307t, 309

impotence and, 333

secondary diabetes and, 30t

in Steno-2 Trial, 69

in UKPDS, 308

$\beta$ -Cell

calcium influx into, 152

destruction, in type 1 diabetes, 29

exhaustion, 73, 169

failure, 23, 188, 238

function

colesevelam and, 156

compensation for insulin resistance, 22

decreased, in type 2 diabetes, 23

exenatide and, 203-204, 207-208

GLP-1 and, 199, 202

HOMA-B assessment of, 87, 95, 122, 203-204

insulin therapy and, 238

liraglutide and, 214

nateglinide and, 152

rosiglitazone and, 85, 87, 93

saxagliptin and, 135

sitagliptin and, 122, 123

genes, 202

GLP-1 receptors on, 199

granules, 238

hormones. See *Amylin*; *Insulin*.

potassium channel regulation in, 149, 152

Bethanechol, in treatment of neurogenic bladder, 332

Bicarbonate treatment

for diabetic ketoacidosis, 290, 292

for HHNS, 296

Biguanide. See *Metformin*.

Bile acid sequestrants (colesevelam; Welchol), 76t, 155-159, 317

action mechanisms, 155-156

adverse events, 157-158, 317

clinical efficacy, 156-157, 158-159

in combination therapy, 155

contraindications, 159

dosage, 76t, 159

hyperlipidemia, use for, 155

other than colesevelam, 317

prescribing considerations, 159

in treatment of diabetic dyslipidemia, 315, 315t, 316t, 317

Blacks. See *African Americans*.

Bleeding, A1C and HbA<sub>1c</sub> testing and, 259

Blindness, diabetes and, 319

Blood glucose monitoring. See *Glucose monitoring*.

Blood pressure. See also *Hypertension*; *Hypotension*, *orthostatic*.

cardiovascular risk assessment and, 257

Blood pressure (*continued*)

decrease with ramipril, 348

decrease with rosiglitazone, 348

diet and, 49

hypertension, 305-310

in metabolic syndrome, 44t

monitoring, 257

rosiglitazone and, 93

target/goal levels, 305

treatment of, in Steno-2 Trial, 69

Bloodletting devices, advances in, 278-279

BluGen HypoKit, 298

Blurred vision, 37, 297, 302

Body fat, distribution of, 32, 34. See also *Obesity*.

pioglitazone and, 105

Body mass index (BMI), 37, 345, 352

Body weight. See *Weight*.

Brainstem hemorrhage, 287

Breeze 2 Blood Glucose Monitoring System, 267t

Bromocriptine mesylate (Cycloset), 76t, 159-162

action mechanism, 160

adverse events, 161, 162

clinical efficacy, 160-161

combination therapy

with metformin, 254

with SFU, 160-161

contraindications/cautions, 162

Cycloset Safety Trial, 161, 162

dosage, 76t, 162

FDA approval of, 159

glycemic control with, 160-161

hypoglycemia and, 161

prescribing considerations, 162

Byetta. See *Exenatide*.

C-peptide levels, 85, 135, 148, 170

measurement of, 180

C-reactive protein (CRP), 95, 105, 106

Cachexia syndrome, 328

Calcium channel blockers (CCBs), 306t, 307t, 309-310

in Steno-2 Trial, 69

in treatment of diabetic nephropathy, 326

Calcium supplements, 52t

Caloric intake, 51, 314t. See also *Diet*; *Nutrition*; *Weight*.

Caloric requirements, adult, 51

Candesartan, 309, 326

Candesartan and Lisinopril Microalbuminuria study, 309

*Candida* skin infection, 300t

CAPPP (Captopril Prevention Project), 351t

Capsaicin, topical, for painful neuropathies, 328, 329

Captopril, 308, 351t

Captopril Prevention Project (CAPPP), 351t

Carbamazepine, 328

Carbohydrates. See also *Diet; Nutrition*.  
 complex, 54-55, 314t  
 dietary intake of, 52t, 54-55, 314t  
 in treatment of hypoglycemia, 297-298

Carbuncles, 300t

Cardiovascular reflexes, impaired, in diabetic neuropathy, 327t, 332

Cardiovascular risk, 40-44  
 alcohol intake and, 52t  
 antihypertensive agents and, 307t, 308, 309-310  
 assessment of, 40-44, 257  
 bromocriptine mesylate and, 161, 162  
 calcium channel blockers and, 309-310  
 diabetes and, 40-44, 63, 304  
 diabetes as risk equivalent, 40  
 dietary guidelines for, 54  
 dyslipidemia and, 40-44, 310-311  
 exercise and, 59  
 metformin and, 82  
 pioglitazone and, 99, 105, 106-107, 108  
 reduced  
   in ACCORD and ADVANCE trials, 69-70, 71, 71, 113-114  
   in DREAM trial, 114, 348-349  
   in Steno-2 Trial, 69, 70  
   in UKPDS, 67-69, 67t  
 rosiglitazone and, 85-86, 95, 113-115, 348-349  
 thiazolidinediones (TZDs) and, 84, 95, 99, 111-115, 113t

Cardiovascular status, monitoring in HNNS, 295

CARDS (atorvastatin) trial, 316t

CARE (Cholesterol and Recurrent Events) study, 316t

Carpal tunnel syndrome, 330

Cataracts, antioxidant supplements and, 57

CCBs. See *Calcium channel blockers*.

CCK-8, gastric emptying and, 241

CDC. See *Centers for Disease Control*.

Cellulitis, 300t

Centers for Disease Control (CDC), 357  
 metabolic/dysmetabolic syndrome, code for, 45

Central nervous system, glucose homeostasis and, 160, 238, 240

Central obesity. See *Obesity, central*.

Cerebrovascular accident, 287

Cerebrovascular disease, 304. See also *Macrovascular disease*.

CHD. See *Coronary heart disease*.

CHF (congestive heart failure)  
 metformin and, 82  
 rosiglitazone and, 85-86  
 TZDs and, 111-113, 113t

Children, type 2 diabetes in, 35, 144

Chlorpropamide (Diabinese), 77t, 146  
 hypoglycemia with, 147

Cholecystokinin, bile acid sequestrants and, 155

Cholestasis, 147

Cholesterol and Recurrent Events (CARE) study, 316t

Cholesterol levels, 312t  
 dietary guidelines for, 54

Cholesterol levels (*continued*)  
 lipid-lowering pharmacologic agents for, 314-318, 315t, 316t  
 risk levels for adult diabetic patients, 37  
 target/goal levels, 258t, 312t, 313t, 314t  
 treatment recommendations based on, 311-314, 313t

Chromium supplementation, 56, 69

Cialis (tadalafil), 333-335, 334t

Cimetidine, sildenafil cautions with, 335

Ciprofloxacin HCl, 331

Cisapride, 331

Classification of diabetes mellitus, 29-36, 30t-31t  
 gestational (GDM), 30t, 34-35  
 impaired fasting glucose (IFG), 33t, 34  
 impaired glucose tolerance (IGT), 33-34, 33t  
 other types of, 30t-31t, 33  
 problems with, 35-36  
 type 1, 29-32, 30t  
 type 2, 30t, 32-33

Clinical trials. See *Trials and studies; specific trials by name*.

Clonidine  
 for diabetic diarrhea, 331  
 for diabetic nephropathy, 326

Colesevelam (Welchol), 155-159, 317. See also *Bile acid sequestrants*.  
 action mechanisms, 155-156  
 adverse events, 157-158  
 in algorithm for treatment, 254  
 clinical efficacy, 156-157, 158-159  
 combination therapy  
   with HMG-CoA inhibitor, 156, 317  
   with metformin, 81, 254  
   with SFU, 157, 159  
 contraindications, 158  
 dosage, 76t, 158  
 glycemic control with, 156-157, 158-159, 317  
 hypoglycemia and, 158  
 indications for, 155  
 prescribing considerations, 158  
 tolerability, 317  
 in treatment of diabetic dyslipidemia, 155, 315, 315t, 317

Colestid, 317

Coma, diabetic, infection and, 299

Combination therapy. See *specific agents*.

Complications of diabetes, 285-341  
 acute, 285-302  
   diabetic ketoacidosis (DKA), 285-292  
   hyperosmolar hyperglycemic nonketotic syndrome (HHNS), 292-296  
   hypoglycemia, 285, 296-299  
   infection, 299, 300t-301t  
   quality of life, 285, 302  
 delay/prevention of, with glycemic control, 253, 303-304  
 early detection and treatment, reduction with, 25-26, 33, 303-304  
 long-term, 303-341  
   diabetic nephropathy, 323-327  
   diabetic neuropathy, 327-336

Complications of diabetes, long-term (*continued*)

- diabetic retinopathy, 319-323
- dyslipidemia, 310-318
- foot disorders, 336-337
- hypertension, 305-310
- macrovascular disease, 304-318
- microvascular complications, 329-336
  - metabolic, 285-299
  - monitoring/tests for, 257
  - postprandial hyperglycemia and, 65
- Computer software programs, use in SMBG, 278
- Confusion
  - HHNS and, 293
  - hypoglycemia and, 297
- Congestive heart failure (CHF). See *CHF*.
- Constipation, 157, 317
- Continuous glucose monitoring systems, 270t-271t
- Contour Blood Glucose, 267t
- Coronary artery disease, 304. See also *Macrovascular disease*.
  - bypass grafting (CABG), in Steno-2 Trial, 70
  - reduction with type 2 diabetes treatment, 66
- Coronary heart disease (CHD)
  - dysmetabolic syndrome X and, 45t
  - risk factors for, 41, 44
- Cost-effectiveness of screening, 343, 352
- Cranial mononeuropathies, 330
- Creatinine
  - clearance
    - metformin and, 82
    - sitagliptin and, 128
  - in diabetic ketoacidosis, 289t
  - in diabetic nephropathy, 323, 324, 325
  - testing/monitoring for, 317-318
- Creatinine phosphokinase (CPK), 317-318
- CRP. See *C-reactive protein (CRP)*.
- Cushing's syndrome, diabetes secondary to, 30t
- Cutaneous infections, 300t
- Cycloset Safety Trial, 161, 162
- Cycloset. See *Bromocriptine mesylate*.
- Cytochrome P-450 enzymes
  - rosiglitazone and, 84
  - saxagliptin and, 142
- Da Qing IGT and Diabetes Study, 343-345, 344t
- DCCT. See *Diabetes Control and Complications Trial*.
- Dehydration
  - in diabetic ketoacidosis, 286, 288t, 290
  - in HHNS, 293, 295
- Detemir (Levemir), 170, 192-193
  - in basal bolus insulin strategy, 187-188
  - dosage, 192
  - regimens for, 187
  - switching to and from, 193-194
  - time course of action, 174t, 176

Detemir (Levemir) (*continued*)

- vs NPH, 192-193
- weight gain (reduced) on, 196
- DexCom Seven with Open Choice, 270t-271t, 279
- Dextrose
  - treatment of diabetic ketoacidosis with, 292
  - treatment of HHNS with, 295-296
- DiaBeta (glyburide). See *Glyburide*.
- Diabetes Control and Complications Trial (DCCT), 66
  - glycemic assessment by SMBG, 262-263
  - value of improved glycemic therapy, 253, 303-304, 325
- Diabetes Exercise and Sports Association (DESA), 356
- Diabetes mellitus, 13-20
  - cardiovascular disease risk and, 40-44
  - cause-of-death statistics, 19, 303
  - characteristics of, 29-36, 30t-31t
  - classification, 29-36, 30t-31t
  - diagnosis, 37-46, 38t
  - heterogeneous pathophysiology of, 23-24
  - incidence of, 16-19, 16, 17, 18
  - insulin-dependent. See *Type 1 diabetes mellitus*.
  - non-insulin-dependent. See *Type 2 diabetes mellitus*.
  - prevalence of, 13-16, 14, 15
  - resources and publications on, 355-361
  - secondary to other conditions, 30t-31t
  - subclasses of, 29, 30t-31t
  - symptoms of, 37
- Diabetes Prevention Program (DPP), 344t, 345-346
- Diabetes prevention trials. See *Primary prevention trials, diabetes*.
- Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication. See *DREAM Trial*.
- Diabetes Warranty Program, 40, 42-43
- Diabetic dyslipidemia. See *Dyslipidemia*.
- Diabetic ketoacidosis (DKA), 285-299
  - compared with HHNS, 293, 294t
  - differential diagnosis, 287-288
  - factors affecting development of, 285-287
  - laboratory evaluation, 288, 289t
  - pathophysiology, 287
  - precipitating factors, 286-287
  - signs and symptoms, 287-288, 288t
  - treatment, 254, 288-292
    - bicarbonate therapy, 290, 292
    - colesevelam not recommended for, 159
    - fluid and electrolyte replacement, 290
    - insulin therapy, 290, 291
    - length of, 292
    - phosphate replacement, 290, 292
    - potassium replacement, 290, 291-292
    - saxagliptin not recommended for, 141
    - sitagliptin not recommended for, 128
- Diabetic nephropathy, 323-327
  - definition, 323
  - evaluation/screening for, 324-325

- Diabetic nephropathy (*continued*)
- factors contributing to, 323-324
  - microalbuminuria in, 323
  - nephrotoxic drugs and, 324
  - treatment, 325-327
    - antihypertensive therapy in, 309, 324, 325, 326
    - improving glycemic control, 325-326
    - protein restriction, 326-327
- Diabetic neuropathy, 327-336
- categories of, 327-336, 327t
  - autonomic, 327t, 330-336
  - diabetic amyotrophy, 327t, 330
  - diabetic diarrhea, 327t, 331
  - gastroparesis, 327t, 330-331
  - impaired cardiovascular reflexes, 327t, 332
  - mononeuropathy, 327t, 330
  - neurogenic bladder, 327t, 332
  - sensorimotor peripheral, 327-330, 327t
  - sexual dysfunction, 327t, 332-336
  - symmetric distal neuropathy, 327t, 328-329, 329
  - painful neuropathies, 328-329, 329
  - prevalence of, 327
  - treatment, 327-336
    - of painful neuropathies, 328-329, 329
- Diabetic retinopathy, 319-323
- categories of, 319-321
    - nonproliferative, 319-320, 320
    - preproliferative, 320, 321
    - proliferative, 321
  - early diagnosis, value of, 16
  - evaluation and referral, 321-322, 322t
  - glycemic control and, 223
  - patient education about, 319
  - referral, reasons for, 322t
  - treatment, 322-323
- Diabinese. See *Chlorpropamide*.
- Diagnosis of diabetes, 37-46, 38t
- asymptomatic presentation, 37
  - cardiovascular risk assessment and, 40-44
  - criteria for, 33t, 38t, 254
    - fasting blood glucose, 13-14, 38t
    - plasma glucose concentration, 38t
  - early, importance of, 19, 25-26, 33, 64, 72
  - glucose testing in, 38-40, 38t
  - medical evaluation, 40, 42-43
  - problems with, 35-36
- Diagnosis of impaired fasting glucose (IFG), 25, 33t, 34
- Diagnosis of metabolic/dysmetabolic syndrome, 44-45, 44t, 45t
- Diarrhea, diabetic, 327t, 331
- DIAS (fenofibrate) trial, 316t
- Diet, 47-58. See also *Nutrition; Obesity; Weight*.
- caloric intake, 51, 314t
  - clinical trials involving, 343-346, 344t
  - dietary guidelines (USDA), 49-50
- Diet (*continued*)
- dietary recommendations, 51-57, 52t
    - alcohol, 52t, 57
    - carbohydrates, 52t, 54-55, 314t
    - fat substitutes, 56
    - fats, 52t, 53-54, 314t
    - fiber, 54, 331
    - fructose, 55
    - protein, 53
    - salt, 52t
    - sucrose (sugar), 52t, 55
    - supplements, 52t, 56-57
    - sweeteners, 55-56
  - for dyslipidemia, 54, 315t
  - exercise combined with, 44, 49, 63-64
  - low-salt, for hypertension, 305
  - monitoring and assessment of, 47-48
  - prescriptions, 52t
  - self-monitoring of blood glucose recommendations with, 273-274
- Dietician, registered, 48
- Digoxin, 82
- Dipeptidyl peptidase-IV inhibitors. See *DPP-IV inhibitors*.
- Diphenoxylate (Lomotil), for diabetic diarrhea, 331
- Diuretics, 307t, 310, 326
- potassium supplementation and, 56
  - secondary diabetes and, 30t
- Division of Diabetes Translation, 357
- Domperidone, 331
- Dopamine receptor agonist (bromocriptine mesylate), 76t, 159-162. See also *Bromocriptine mesylate*.
- Doxycycline hyclate, 331
- DPP (Diabetes Prevention Program), 344t, 345-346
- DPP-IV
- degradation of GLP-1, 116, 202
  - resistance to degradation by, for GLP agonists, 202
- DPP-IV inhibitors (saxagliptin; sitagliptin), 76t, 116-142. See also *Saxagliptin; Sitagliptin*.
- advantages of, 117
  - in algorithm for treatment, 254
  - combination agent with metformin (Janumet), 77t, 128-129
  - combination therapy. See *Saxagliptin; Sitagliptin*.
  - dosing, 76t, 128-129
  - efficacy and safety trials, 117-127, 130-137
  - FDA approval of, 116
  - indications for, 117, 129
  - renal disease patients, use in, 127
  - summary, 142
- DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) trial, 114, 344t, 348-350, 349
- Duetact (pioglitazone/glimepiride), 78t, 102
- glycemic control with, 102, 103t, 104t
  - prescribing considerations, 110
- Dymelor (acetohexamide), 77t, 146

Dyslipidemia, 310-318. See also *Cholesterol levels; Lipid levels; and specific classes of lipids.*  
cardiovascular risk and, 40-44, 310-311  
characteristic abnormalities, 310-311  
in criteria for dysmetabolic syndrome X, 45t  
diabetes secondary to, 30t  
fructose limitation advised for, 55  
IFG and IGT as risk factors for, 25  
lipid levels, low-to-high values for, 302t  
metabolic syndrome, risk and, 40, 45t  
reduction with type 2 diabetes treatment, 66  
screening for, 302t, 311  
treatment recommendations, 41-42, 311-318, 313t  
  ADA order of priorities for, 314, 315t  
  clinical trials on pharmacologic agents, 316t  
  dietary therapy, 54, 315t  
  NCEP stepped approach, 311-314  
  pharmacologic therapy, 315-318, 315t, 316t  
Dysmetabolic syndrome X, 44-45, 45t  
Dyspepsia, 157  
Dyspnea, in diabetic ketoacidosis, 287, 288t

Ear infections, 301t

Early detection and management, benefits of. See also *Prevention of diabetes.*  
increased effectiveness of nonpharmacologic therapy, 64  
prevention/slowing of disease progression, 26, 73, 84, 253, 319, 343, 350, 352  
reduction in complications, 25-26, 33, 303-304  
reduction of mortality, 19, 84, 318-319

Early Treatment Diabetic Retinopathy Study, 322-323

EASD. See *European Association for the Study of Diabetes.*

Eclipse monitoring system, 267t

Edema  
  macular, 322  
  thiazolidinediones and, 111-113, 113t

Education. See *Patient education.*

Elderly patients  
  acarbose in, 143  
  cautions in, 176-178  
  glipizide in, 148  
  HHNS in, 292  
  hypoglycemia susceptibility of, 263  
  insulin-pump therapy and, 188-189  
  late-onset type 1 diabetes (LADA) in, 189, 286, 290  
  nateglinide in, 155  
  SFUs in, 147

Electrocardiogram (ECG), in diabetic ketoacidosis, 291

Electrolytes, in diabetic ketoacidosis, 286, 290

Element monitoring system, 267t

Endocrinopathies, diabetes secondary to, 30t

Environmental factors in type 2 diabetes, 22, 24-25

Erectile dysfunction. See *Sexual dysfunction.*

Erythromycin lactobionate, 331, 335

ESRD (end stage renal disease). See *Renal disease.*

Ethnicity

  prevalence of diabetes and, 13-14, 15, 32

  risk for diabetes and, 23, 34, 37

  screening for diabetes and, 352

Etiology of type 2 diabetes, 21-23

European Association for the Study of Diabetes (EASD), 75, 253, 265

Exenatide (Byetta), 202-214

  in algorithm for treatment, 254

$\beta$ -cell function with, 203-204, 207-208

  body weight effects of, 205t, 206-207, 209-213, 209, 211, 213

  combination therapy, 203

  with metformin, 81, 203, 204-206, 205t, 207-208, 208-209, 209, 211, 212, 254

  with SFUs, 203, 204-206, 205t, 209, 211, 212

  with TDZs, 203, 206, 208-209

  contraindications, 214

  dosage and administration, 214, 215t

  glycemic control with, 204-213

  half-life, 203

  hypoglycemia and, 204-206, 207

  indications for, 203

  side effects, 207

  trials and studies of, 203-213

    comparative and long-term open-label trials, 206-213

      82-week studies, 208-212, 211, 213

      exenatide vs insulin glargine, 206-208, 210

      2-year data, 212-213

  HEELA, 207

  phase 2 clinical trials, 203-204

  phase 3 clinical trials (30-week), 204-206, 205t, 208-209

  vs insulin glargine, 206-208, 210

  vs liraglutide, 229, 230

Exendin-4, 202-203

Exercise, 59-62

  benefits of, 52t, 59

  combined with diet, 44, 49, 51, 63-64

  clinical trials involving, 343-346, 344t

  as first line therapy, 44

  as component of therapy, 44, 52t, 59

  guidelines, 61t

  hypoglycemia induced by, 59-60, 299

  macrovascular disease risk reduction with, 305

  precautions and considerations, 59-60, 61t

  prescription, 60, 61t

  prevention of diabetes and, 59

  safety in, 59-60, 61t

  self-monitoring of blood glucose recommendation with, 60

  in treatment of hypertension, 305

  in treatment of metabolic syndrome, 44

  in weight loss program, 44, 51, 59, 60

Eyes. See also *Diabetic retinopathy.*

  blurred vision, 37, 297, 302

  diabetic ketoacidosis and, 288t

  routine testing/exams in diabetes, 257, 322

Family history  
 as risk factor for CHD, 41  
 as risk factor for diabetes, 21, 32, 37, 345

Farsenoid X receptors, 155

Fasting hyperglycemia, 21-22

Fasting plasma glucose. See also *specific agents*.  
 as diagnostic criterion, 13-14, 25, 37t, 39, 254  
 impaired. See *Impaired fasting glucose (IFG)*.  
 in metabolic syndrome, 44t  
 as predictive of glycemic control, 179  
 target/goal levels, 66t, 304  
 testing for, 25, 39

Fat  
 body fat distribution, 32, 34. See also *Obesity; Weight*.  
 pioglitazone and, 105  
 dietary. See also *Diet; Dyslipidemia; Nutrition*.  
 benefits of restriction of, 53-54  
 incidence of diabetes and, 18-19, 22  
 recommendations for, 52t, 53-54, 314  
 restriction in dyslipidemia, 314, 314t  
 substitutes, 56

Fatigue  
 diabetic ketoacidosis and, 285, 287  
 hypoglycemia and, 297

Fatty liver (steatohepatitis), 111

FDPS (The Finnish Diabetes Prevention Study), 344t, 345

Fenofibrate (Tricor), 315t, 316t, 317-318

Fetal hemoglobin, glycemic testing results and, 260

Fiber, dietary, 54, 331

Fibrates, 315t, 316t, 318  
 diabetic neuropathy and, 327  
 in Steno-2 Trial, 69

Fibric acid derivatives, 315t, 316t, 318

Fifty50 Control Blood Glucose Monitoring System, 267t

Fingerstick devices, advances in, 278-279

Finnish Diabetes Prevention Study (FDPS), 344t, 345

Flatulence, 143, 144

Fludrocortisone, 332

Fluid replacement, in diabetic ketoacidosis, 290

Fluvastatin, 315

Folic acid supplements, 52t, 69

Foot disorders in diabetes, 330, 336-337  
 foot exam, 257  
 guidelines for foot care, 336-337, 338t

Fortamet, 76t, 83. See also *Metformin (MET)*.

FPG. See *Fasting plasma glucose*.

FreeStyle blood glucose monitors, 267t

FreeStyle Navigator (continuous glucose monitoring system), 271t, 279

Fructosamine measurement, 260-261, 261

Fructose, 55

Furunculosis, 300t

Gabapentin (Neurontin), 328, 329

GAD. See *Glutamic acid decarboxylase*.

Gastric emptying, 200  
 amylin/pramlintide, effect on, 238, 240-241, 240  
 delayed, in gastroparesis, 330  
 GLP-1 and, 200, 241  
 postprandial glucose levels and, 65, 240-241

Gastric inhibitory peptide (GIP), 237

Gastroenteritis, 288

Gastrointestinal symptoms  
 bile acid sequestrants and, 157, 317  
 bromocriptine mesylate and, 161  
 diabetic ketoacidosis and, 286, 287, 288t  
 exenatide and, 207  
 in HHNS, 293  
 liraglutide and, 229-230  
 metformin and, 81, 121  
 miglitol and, 144  
 pramlintide and, 246-247, 248  
 SFUs and, 146  
 sitagliptin and, 121

Gastroparesis, 327t, 330-331

GDM. See *Gestational diabetes mellitus (GDM)*.

Gemfibrozil (Lopid), 315t, 316t, 317-318

Gender, prevalence of diabetes and, 13, 37

Genetic syndromes, diabetes secondary to, 30t

Genetics  
 component in cardiovascular disease, 40  
 component in type 2 diabetes, 18-19, 21, 32  
 thrifty gene hypothesis, 18-19

Gestational diabetes mellitus (GDM), 34-35  
 characteristics of, 30t, 34-35  
 diagnosis, 39-40  
 previous, diabetes screening and, 352  
 as risk factor for type 2 diabetes, 35, 37  
 screening for, 35, 39-40

Gila monster, 202, 203

GIP (gastric inhibitory peptide), 237

GIP (glucose-dependent insulinotropic polypeptide), 116, 199, 200

Glargine (Lantus), 170, 193-195. See also *Insulin therapy*.  
 combination therapy, 191, 226t-227t  
 dosage, 195  
 hypoglycemia with, 185, 185  
 ORIGIN study, 350-352  
 regimens for, 187  
 switching to and from, 193-194  
 time course of action, 174t, 176  
 transition to, 188  
 Treat-to-Target Study, 184-185, 184, 193  
 vs exenatide, 206-208, 210

Glicazide, in Steno-2 Trial, 69

Glimepiride (Amaryl), 77t, 146, 148. See also *Sulfonylureas*.  
 combination formulations  
 with pioglitazone (Duetact), 78t, 102  
 with rosiglitazone (Avandaryl), 78t, 91-93

- Glimepiride (Amaryl) (*continued*)  
 combination therapy  
   with insulin, 148  
   with liraglutide, 217-223, 218t-219t, 220t-221t, 226t-227t  
   with sitagliptin, 125-126  
 dosage, 77t, 148  
   for Avandaryl, 78t  
   for Duetact, 78t  
 lack of weight gain with, 148  
 vs liraglutide, 216-217, 218t
- Glinides, 77t, 149-155. See also *Nateglinide*; *Repaglinide*.  
 action mechanisms, 149, 152  
 in algorithm for treatment, 254  
 combination therapy  
   with biguanide (metformin), 77t, 81, 152  
   with TZDs, 149  
 dosing/prescription considerations, 77t, 151, 154-155  
 glycemic control with, 150-151, 153-154  
 hypoglycemia and, 296  
 side effects, 152, 155
- Glipizide (Glucotrol), 77t, 146, 148-149. See also *Sulfonylureas*.  
 combination therapy  
   with metformin (Metaglip), 78t, 83  
   with sitagliptin, 125  
 dosing, 77t, 148-149  
   once-a-day, 146  
 extended release (Glucotrol XL), 77t, 146, 148-149  
 safety and benefits of, 148
- Glipizide/metformin (Metaglip), 78t. See also *Glipizide*; *Metformin*.  
 Glitazones, 318
- GLP-1 (glucagonlike peptide 1), 116, 199-202. See also *DPP-IV inhibitors*; *GLP-1 analogues*.  
 agonists for, 199-236  
 body weight effects, 201, 232  
 degradation by DPP-IV, 116  
 DPP-IV inhibitors and, 116-117  
 exogenous administration of, 199-202  
 functions of, 199-202  
 gastric emptying and, 200, 241  
 glucoregulatory effects of, 199-202  
 half-life, 202  
 production of, 199, 200  
 receptors, 199
- GLP-1 analogues, 202-232. See also *specific agents*.  
 combination therapy with metformin, 81  
 dosing and administration, 214, 215t, 231-232  
 efficacy and safety trials, 203-229  
 indications for, 203, 214  
 specific agents  
   exenatide (Byetta), 202-214  
   liraglutide (Victoza), 214-232  
   summary of, 232
- GLP agonists, 199-236. See also *GLP-1 analogues*.  
 multihormonal control of glucose and, 200
- GLP agonists (*continued*)  
 production of, 199  
 rationale for use, 199-202
- Glucagon, 64-65, 200, 237  
 intramuscular, for severe hypoglycemia, 298  
 proglucagon, 199  
 suppression of hypersecretion, 64-65, 241  
   with amylin/pramlintide, 239, 240, 241  
   with GLP-1, 199, 201
- Glucagonlike peptide. See *GLP-1*.
- Glucagonoma, diabetes secondary to, 30t
- Glucocard X-Meter, 268t
- GlucoCom Code Free, 268t
- Glucophage (metformin), 76t. See also *Metformin (MET)*.  
 in Diabetes Prevention Program (DPP), 344t, 345-346
- Glucophage XR, 76t, 83. See also *Metformin (MET)*.
- Glucoregulatory hormones. See also *specific hormones*.  
 amylin, 237-240  
 incretin hormones, 116, 199-202, 200  
 insulin. See *Insulin*.  
 multihormonal control of glucose homeostasis, 200
- Glucose-dependent insulinotropic polypeptide (GIP), 116, 199, 200
- Glucose homeostasis, 238-240, 240  
 glucose appearance and disappearance in, 238-240, 240  
 multihormonal control of, 200, 237  
 new paradigm for, 238-240, 240. See also *Pramlintide therapy*.
- Glucose intolerance, disorders of, 30t-31t
- Glucose levels, 38-40, 38t. See also *Glycemic control*; *Plasma glucose concentration (PGC)*; *Postprandial glucose (PPG)*.  
 in diabetic ketoacidosis, 289t, 291, 294t  
 in HNNS, 294t, 295  
 measuring, 257-259  
 monitoring. See *Glucose monitoring*.  
 multihormonal control of, 200, 237  
 normal, 38t, 252t  
 targets/goals for, 252t, 304
- Glucose monitoring, 257-284  
 advances in, 278-283  
   bloodletting devices, 278-279  
   computer-assisted data analysis, 271t, 279  
   continuous glucose monitoring, 270t-271t, 279-283  
   noninvasive monitoring, 283  
 interstitial glucose measurements, 283  
 measuring glycated hemoglobin, 259-260  
 measuring plasma glucose levels, 257-259  
 self-monitoring, 261-283, 266t-272t. See also *Self-monitoring of blood glucose (SMBG)*.  
   blood glucose monitors, 266t-270t  
   continuous glucose monitoring systems, 270t-271t  
   recommendation for all diabetes patients, 265  
 timing of, 258-259
- Glucose production, hepatic  
 amylin/pramlintide action on, 238, 240  
 insulin and amylin actions on, 238, 240

Glucose production, hepatic (*continued*)  
 in pathogenesis of type 2 diabetes, 21-22, 22, 64  
 in transition from IGT to type 2 diabetes, 22, 24, 25, 25  
 weight loss and, 49

Glucose sensitivity, weight loss and, 49

Glucose testing, 38-40, 38t. See also *Glucose monitoring*.  
 oral glucose tolerance test (OGTT), 25, 38t, 39

Glucose tolerance, impaired. See *Impaired glucose tolerance*.

Glucose toxicity, 23, 63  
 diabetic ketoacidosis and, 286  
 insulin therapy for, 80, 147, 170

Glucotrol, Glucotrol XL. See *Glipizide*.

Glucovance (glyburide/metformin), 78t, 82-83. See also *Glyburide*;  
*Metformin*.

Glulisine (Apidra), 170, 190  
 time course of action, 170, 172-173, 174t

Glumetza, 76t, 83. See also *Metformin (MET)*.

Glutamic acid decarboxylase (GAD) antibodies, 36, 170, 189

Glyburide (DiaBeta, Micronase, Glynase PresTab), 77t, 146. See also  
*Sulfonylureas*.  
 in ADOPT trial, 85-86, 86  
 cautions for, 146  
 combination formulation with metformin (Glucovance), 78t, 82-83  
 combination therapy, with saxagliptin, 135-137, 138t-139t  
 dosing considerations, 77t  
 Glynase PresTab, 77t, 149  
 hypoglycemia and, 149  
 vs rosiglitazone, 84-86, 86

Glyburide/metformin (Glucovance), 78t, 82-83

Glycated hemoglobin assay/measurement, 259-260. See also *Glucose monitoring*;  
*Glycosylated hemoglobin (A1C)*.

Glycated proteins, measurement of, 260-261, 261

Glycation, defined, 260

Glycemic control. See also *Glucose homeostasis*; *Glucose monitoring*;  
*specific treatments and agents*.  
 in algorithm for treatment, 253, 254-255  
 benefits of, 66-67, 67t, 73, 319, 325  
 diabetic nephropathy and, 325-326  
 FBG level as predictor of, 179  
 intensive therapy for, 65-72  
 monitoring, 257-284  
 targets/goals for, 65, 66t, 69-70, 72, 252t, 253, 258t, 304  
 weight loss and, 49

Glycosylated hemoglobin (A1C). See also *specific treatments and agents*.  
 measurement of, 259-260  
 correlation with diabetic control, 259  
 false lows and highs, 259-260  
 home measurement kits, 260  
 lack of standardization in, 39  
 monitoring, 257-284  
 normal value, 252t  
 postprandial hyperglycemia and, 65  
 targets/goals for, 66t, 71, 72, 252t, 253, 258t, 304

Glycosylated hemoglobin (A1C) (*continued*)  
 trials and studies  
 High A1C Study, 85  
 in Steno-2 Trial, 69  
 UKPDS, 66, 68-69, 68  
 VADT, 70

Glynase PresTab (glyburide), 77t. See also *Glyburide*.  
 Glyset. See *Miglitol*.

Guardian Real-Time, 271t, 279

Gut hormones. See *Incretin hormones*.

Hagedorn (neutral protamine Hagedorn). See *NPH*.

HDL. See *High-density lipoprotein (HDL)*.

Headache, 128, 141, 161, 288t

Healing, abnormal, 37

Heart of Diabetes, The (American Heart Association), 357

Heart Outcomes Prevention Evaluation trial (HOPE), 308, 351t

HEELA (Helping Evaluate Evaluation in Overweight Patients With  
 Diabetes Compared With Long-Acting Insulin) study, 207

*Heloderma suspectum* (Gila monster), 202

Helsinki trial, 316t

Hematologic reactions, 147

Hemochromatosis, 30t, 333

Hemolytic anemia, 259

Hepatic glucose production. See *Glucose production, hepatic*.

Hepatocyte nuclear factor 4 alpha 4, 155

Herbal supplements, 57

HHNS. See *Hyperosmolar hyperglycemic nonketotic syndrome*.

High A1C Study, 85

High-density lipoprotein (HDL), 37, 310  
 cholesterol  
 CV risk and, 41-43, 310-311  
 levels, 312t  
 low, treating, 318  
 in metabolic syndrome, 44t  
 raising, 315t, 318  
 rosiglitazone and, 93  
 saturated fat intake and, 54  
 target/goal level, 258t, 312t  
 in metabolic/dysmetabolic syndrome, 44t, 45t  
 pioglitazone and, 102, 105

Hispanic/Latino Americans. See also *Race/ethnicity*.  
 incidence of diabetes in, 18  
 prevalence of diabetes in, 13, 15, 32  
 risk of diabetes in, 37

HMG-CoA reductase inhibitors, 45, 155, 315-316, 315t, 316t  
 combination therapy, with colesevelam, 155  
 contraindications and cautions, 317

Homeostasis, glucose. See *Glucose homeostasis*.

Homeostasis model assessment (HOMA), 87  
 $\beta$ -cell function (HOMA-B), 87, 95, 122, 203-204

HOPE (Heart Outcomes Prevention Evaluation trial), 308, 351t

Hormones. See *Glucoregulatory hormones*.

HPS (simvastatin) trial, 316t

- Humalog (lispro), 170, 189  
 for diabetic ketoacidosis, 291  
 time course of action, 172-173, 174t, 176
- Humalog Mix  
 Humalog Mix 50/50, 170, 190  
 Humalog Mix 75/25, 170, 186, 190  
 time course of action, 175t
- Human insulin, 170, 171. See also *Insulin therapy*.
- Humulin 70/30, 50/50, 175t
- Huntington's chorea, diabetes secondary to, 30t
- Hypercoagulability, dysmetabolic syndrome X and, 45t
- Hyperglycemia, 22, 63, 64-65  
 classic symptoms of, 254  
 diabetic ketoacidosis and, 286, 287, 288t  
 diabetic nephropathy and, 323, 325, 326  
 diabetic retinopathy and, 319  
 in diagnosis of diabetes, 29, 254  
 fasting, 21-22, 64  
 postprandial, 64-65  
 as common denominator in diabetes syndromes, 29  
 importance of controlling, 64-65  
 target PPG levels, 66t  
 premeal, techniques to adjust for, 274t  
 prolonged, 63  
 severe, SMBG in preventing, 263
- Hyperinsulinemia, 22, 195
- Hyperosmolar hyperglycemic nonketotic syndrome (HHNS), 292-296  
 compared with diabetic ketoacidosis, 293, 294t  
 diagnosis, 295  
 laboratory evaluation, 294t, 295  
 pathophysiology, 293  
 symptoms and signs of, 293-295, 294t  
 treatment of, 295-296
- Hyperprolactinemia, 333
- Hypertension, 305-310  
 antihypertensive drugs, 305-310, 306t, 350  
 clinical trials involving, 351t  
 diabetes risk reduction with, 350, 351t  
 potential benefits of, 307t  
 potential complications of, 306t  
 secondary diabetes and, 30t  
 side effects of, 305, 306t  
 blood pressure goals, 305  
 in criteria for dysmetabolic syndrome X, 45t  
 diabetic nephropathy and, 323-324, 325  
 IFG and IGT as risk factors for, 25  
 as risk factor for CHD, 41  
 as risk factor for diabetes, 37  
 as risk factor for metabolic syndrome, 41, 45t  
 treatment of, 44-45, 305-310, 306t  
 in treatment of metabolic syndrome, 44-45
- Hypertriglyceridemia, 310, 318. See also *Dyslipidemia*.
- Hyperuricemia, dysmetabolic syndrome X and, 45t
- Hyperventilation, diabetic ketoacidosis and, 287, 288, 288t
- Hypoglycemia, 285, 296-299  
 causes of, 296  
 diabetic ketoacidosis and, 288  
 education about, 178, 299  
 emergency kits for, 298  
 exercise and, 59-60  
 factors contributing to, 296  
 glucagon administration for, 298  
 nocturnal, 297, 299  
 prevention of, 178, 263, 299  
 safety of acarbose, 143-144  
 severe, 297, 298  
 $\beta$ -blockers and, 309  
 pramlintide and, 247  
 as side effect  
 of bromocriptine mesylate, 161  
 of chlorpropamide, 147  
 of colesevelam, 158  
 of exenatide, 204-206  
 of glinides, 296  
 of insulin therapy, 178, 196, 237, 296  
 of liraglutide, 231  
 of pramlintide, 247  
 of saxagliptin, 141  
 of SFUs, 146, 147, 296  
 of sitagliptin, 120, 126-127, 128  
 signs of, 296-297  
 SMBG and, 196, 263, 299  
 treatment of, 297-299
- Hyponatremia, with sulfonyleureas, 146
- Hyporeflexia, in diabetic ketoacidosis, 288t
- Hypotension, orthostatic  
 antihypertensive drugs and, 306t, 309  
 bromocriptine mesylate and, 161  
 in diabetic neuropathy, 332
- Hypothermia, in diabetic ketoacidosis, 288t
- Hypotonia, in diabetic ketoacidosis, 288t
- ICD-9 code (for metabolic/dysmetabolic syndrome), 45
- IDF (International Diabetes Federation), 358-359
- IFG. See *Impaired fasting glucose*.
- IGT. See *Impaired glucose tolerance*.
- Imodium (loperamide), for diabetic diarrhea, 331
- Impaired fasting glucose (IFG), 34, 343  
 diagnostic criteria for, 25, 33t, 34  
 in DREAM trial, 348-350, 349  
 in metabolic/dysmetabolic syndrome, 44t, 45t  
 in ORIGIN study, 352  
 as risk factor, 14, 25, 37
- Impaired glucose tolerance (IGT)  
 as cardiovascular risk factor for, 41  
 characteristics of, 30t-31t, 33-34  
 diagnosis, 24-25, 25, 33-34  
 criteria for, 33t

Impaired glucose tolerance (IGT) (*continued*)

- glucose production in, 21-22
- insulin secretion and, 23
- macrovascular disease and, 34
- metabolic syndrome and, 41
- oral glucose tolerance test and, 25
- as risk factor, 25, 37, 343
- screening for, 25
- transition to type 2 diabetes, 22-23, 24, 34
  - factors influencing, 34
- trials and studies
  - ACT-NOW trial, 350
  - Da Qing IGT and Diabetes Study, 343-345, 344t
  - DREAM trial, 344t, 348-350, 349
  - Finnish Diabetes Prevention Study (FDPS), 344t, 345
  - ORIGIN study, 352
  - STOP-NIDDM, 344t, 347

Impotence. See *Sexual dysfunction*.

Incidence of diabetes, 16-19, 32

- by age, 16-18, 17, 18
- definition of, 16
- factors affecting, 18-19
- increase in, 16-17, 16, 18

Incretin effect, 116, 199

Incretin hormones, 116, 199-202, 200. See also *DPP-IV inhibitors*; *GLP-1 analogues*.

- DPP-IV inhibitors and, 116-142
- effects of, 116, 199-202
- GLP-1 analogues and, 202-232
- rationale for use, 199-202
- summary of uses and effects, 232

Incretin mimetics. See *GLP-1 analogues*.

Indapamide, 326

Indian Health Services (IHS), 357-358

Indians, American. See *American Indians*.

Infection, 299, 300t-301t

- common infections in diabetes patients, 300t-301t
- development of diabetic ketoacidosis and, 286
- as symptom of diabetes, 37

Insulin. See also *Insulin therapy*.

- action mechanism, 170, 200, 238
- normal time course of, 176
- allergy to, 171
- antibodies to, 171, 178
- cosecretion with amylin, 238, 239
- deficiency
  - absolute, 24, 285
  - $\beta$ -cell exhaustion and, 169, 238
  - in diabetic ketoacidosis, 285
  - factors in, 169
- GLP-1 and, 199-200, 201
- multihormonal control of, 200
- in Steno-2 Trial, 69
- to treat hyperglycemia, 80

Insulin (*continued*)

- types of preparations, 170, 174t-175t
  - human, 170, 171
  - insulin analogues, 170-173
  - new types of, 189-195
  - premixed, 170-171
  - recombinant DNA, 192, 193
  - selecting, 170-176
  - in UKPDS, 66

Insulin-dependent diabetes. See *Type 1 diabetes mellitus*.

Insulin receptor abnormalities, diabetes secondary to, 30t

Insulin resistance, 21-23, 32, 63, 188

- cardiovascular disease and, 40
- compensated, 22-23
- early damage from, 14-16, 83
- factors influencing, 40-41
- metabolic/dysmetabolic syndrome and, 45t
- present prior to diagnosis, 24
- reduction with TZDs, 83-84
- severe, insulin antibodies and, 171
- syndrome. See *Metabolic syndrome*.
- in transition from IGT to type 2 diabetes, 22-23, 24

Insulin secretion

- impaired, 23, 64
  - diabetes initiation and, 22, 23
  - diabetes progression and, 24
  - prior to onset of hyperglycemia, 22
- in prediabetic or IGT state, 22

Insulin therapy, 169-198. See also *specific formulations/preparations of insulin*.

- action mechanism, 170
- algorithm for, 178, 179, 254
- basal, 171
- benefits of, 170
- bolus, 171, 187
- cautions for, 176-178
- combination therapy, 178-185, 254
  - with acarbose, 143
  - in algorithm for treatment, 254-255
- benefits of, 180-181
- dosing guidelines/calculation, 181, 181t
  - adding predinner premixed insulin to daytime oral medications, 183t
  - maximum dose of oral agent, 183
- with glimepiride, 148
- glycemic control with, 183-184, 184
- most common clinical situation for, 183-184
- patient selection for, 179-180
- patient self-adjustment with SMBG, 182, 182t
- with pramlintide, 237-238, 242, 243, 244, 245
- rationale for, 178-179, 183
- with rosiglitazone, 88
- with SFUs, 147, 148
- with sitagliptin, 117, 126
- timing of doses, 181-182, 181t

Insulin therapy, combination therapy (*continued*)

- Treat-to-Target Study, 184-185, 184
- complications of, 195-196
  - hypoglycemia, 196
  - weight gain, 195-196
- for diabetic ketoacidosis, 290, 291
- dosage
  - self-adjustment via SMBG data, 182, 182t, 275-278
    - guidelines for, 282t
- for HHNS, 295
- hypoglycemia and, 196, 237, 296
  - education about, 178
- indications for, 169
- individual tailoring of, 178
- initiation of, 169, 186-187, 188
- insulin preparations, 170-176
  - fast-acting analogues, 170, 171, 172-173
    - aspart (Novolog), 170, 172-173, 176, 190
    - glulisine (Apidra), 170, 172-173, 176, 190
    - lispro (Humalog), 170, 172-173, 176, 189
    - time course of action, 170, 172-173, 174t, 176
    - ultra-fast (Afrezza), 170
  - human insulin, 170, 171
  - insulin analogues, 170-173
  - intermediate-acting (NPH), 171, 174t
  - long-acting analogues, 170
    - detemir (Levemir), 170, 192-193
    - glargine (Lantus), 170
    - time course of action, 174t
  - newer preparations, 189-195
    - insulin aspart (Novolog), 190
    - insulin detemir (Levemir), 192-193
    - insulin glargine (Lantus), 193-195
    - insulin glulisine (Apidra), 190
    - insulin lispro (Humalog), 189
    - recombinant DNA-produced, 192, 193
  - premixed, 170-171, 190-192
    - advantages of, 191
    - disadvantage of, 191-192
    - Humalog Mix 50/50 (lispro), 190
    - Humalog Mix 75/25 (lispro), 190
    - Novolin 70/30 (NPH-insulin), 191
    - Novolog Mix 70/30 (aspart), 190, 191
    - time course of action, 175t, 190-191
  - regular insulin, 171, 176
  - selection guidelines, 170-176
  - short-acting (regular insulin), 171
    - time course of action, 174t, 176
  - short/fast-acting, 171
    - time course of action, 170, 172-173, 174t, 176
- intensive, 176-178
  - goals of, 176
  - in obese patients, 186
  - patient selection for, 176

Insulin therapy (*continued*)

- intermittent, 171
- ORIGIN study, 350-352
- pump therapy, 177t, 188-189, 254
  - pump with continuous glucose monitoring device, 271t
  - switching regimens to or from, 194
- rationale for, 178-179
- regimens for, 177t
  - basal bolus strategy, 187-188
  - combined with oral agents, 177t
  - continuous subcutaneous insulin infusion (CSII), 254
  - multiple-injection, 177t, 185-188, 254
    - multiple-daily-injection (MDI), 187, 188
  - natural progression in, 169, 178, 188
  - pump therapy, 177t, 188-189
  - single-injection, 177t
  - site of injection and, 172, 178
  - split-mixed, 185, 186-187, 254
  - switching to and from, 193-194
- selection of insulin preparation, 170-176
  - common regimens, 177t
  - factors affecting, 172-173
  - time course of action and, 172, 176
- self-monitoring of blood glucose (SMBG), 274-275
  - dosage adjustment and, 182, 182t
  - record sheet, 276-277
  - time course of action, 172, 172-173, 174t-175t
  - timing of, 52t, 249
- Intensive insulin therapy, 176-178. See also *Insulin therapy*.
- International Diabetes Center at Park Nicollet, 358
- International Diabetes Federation (IDF), 358-359
- Intestinal peptides, 199-202. See also *Incretin hormones*.
- Irbesartan, 326
- Iron, serum, in diabetic impotence, 333
- Islet cell antibody (ICA), 29, 169
- Isophane. See *NPH*.
- Janumet (sitagliptin/metformin), 77t, 128-129
- Januvia. See *Sitagliptin*.
- JDRF (Juvenile Diabetes Research Foundation) International, 359
- Joslin Diabetes Center, 359
- Juvenile Diabetes Research Foundation (JDRF) International, 359
- Ketoacidosis. See *Diabetic ketoacidosis*.
- Ketoneuria in type 2 diabetes, 32
- Ketones
  - in diabetic ketoacidosis, 286, 289t, 291, 294t
  - in HHNS, 294t
  - serum, measurement of, 261
- Ketosis, 286, 292. See also *Diabetic ketoacidosis*.
- Kidney disease. See also *Diabetic nephropathy*.
  - acarbose safety in, 144
- Kidney function. See *Renal function*.

- Kussmaul's respiration  
in diabetic ketoacidosis, 288t  
in HHNS, 293
- Lactic acidosis, metformin therapy and, 81-82
- LADA (Late-onset type 1 diabetes), 189, 286, 290
- LADA (latent autoimmune diabetes in adults), 170
- Lantus. See *Glargine*.
- Laser photocoagulation, 322-323
- Late-onset type 1 diabetes (LADA), 189, 286, 290
- Latent autoimmune diabetes in adults (LADA), 170. See also *LADA*.
- Latino Americans. See *Hispanic/Latino Americans*.
- LDL. See *Low-density lipoprotein (LDL)*.
- LEAD (Liraglutide Effect and Action in Diabetes), 216-229, 218t-219t, 220t-221t, 222, 224t-227t, 228
- Lean type 2 diabetic patients, 64
- Lente, 181, 182t, 193. See also *Ultralente*.
- Levemir. See *Detemir*.
- Levitra (vardenafil), 333-335, 334t
- LIFE study, 351t
- Lifestyle modifications, 47-62, 315t. See also *Diet; Exercise; Nutrition*.  
clinical trials involving, 343-346, 344t  
concurrent with oral agents, 75, 253  
as initial treatment approach, 47, 59, 253, 254  
combined with metformin, 75, 253, 254
- Lifestyle, sedentary, as risk factor for diabetes, 13, 22, 25, 34, 38, 59
- Lipid levels. See also *Dyslipidemia; High-density lipoprotein; Low-density lipoprotein; Triglycerides*.  
for adults (low, borderline, high-risk), 312t  
cardiovascular risk and, 54, 310  
colesevelam and, 155  
dyslipidemia, 310-318  
effect of diet on, 47, 54  
goals for, 41, 258t  
lipid-lowering pharmacologic agents, 69, 314-318, 315t, 316t  
metformin and, 81  
pioglitazone and, 102-105  
rosiglitazone and, 93
- Lipoproteins. See *High-density lipoprotein (HDL); Low-density lipoprotein (LDL)*.
- Liraglutide (Victoza), 214-232  
action mechanism, 214  
adverse events, 229-231  
in algorithm for treatment, 254  
amino acid sequence, 214  
 $\beta$ -cell function and, 156  
body weight effects of, 216, 217, 221t, 223, 224t, 226t, 228-229  
combination therapy, 214  
with glimepiride, 217-223, 218t-219t, 220t-221t, 226t-227t  
with metformin, 214, 223-229, 224t-225t, 226t-227t, 228, 254  
with rosiglitazone, 217-229, 218t-219t, 222, 228  
with SFU, 214  
with TZD, 214  
contraindications, 231-232
- Liraglutide (Victoza) (*continued*)  
dosage and administration, 215t, 231-232  
FDA approval of, 202  
glycemic control with, 214-229  
hypoglycemia and, 231  
indications for, 214  
safety and tolerability of, 229-231  
trials and studies of, 214-229  
phase 2 clinical trials, 214-216  
phase 3 clinical trials, 216-229  
in combination with one OAD, 217-223  
in combination with two OADs, 223-229  
LEAD (Liraglutide Effect and Action in Diabetes), 216-229, 218t-219t, 220t-221t, 222, 224t-227t, 228  
monotherapy (LEAD-3), 216-217, 218t, 220-221t  
vs exenatide, 229, 230  
vs glimepiride, 216-217, 218t  
Lisinopril, in ALLHAT, 351t
- Lispro (Humalog), 170, 189. See also *Humalog; Humalog Mix*.  
combined with pramlintide, 242, 243  
time course of action, 172-173, 174t
- Liver function  
fatty liver (steatohepatitis), 111  
glipizide and, 148  
monitoring, 110, 111  
nateglinide and, 155  
oral agent contraindications/cautions for, 111
- Lomotil (diphenoxylate), for diabetic diarrhea, 331
- Long-term complications. See *Complications of diabetes, long-term*.
- Loop diuretics, 82, 306t, 307t, 310, 326
- Loperamide (Imodium), for diabetic diarrhea, 331
- Lipid. See *Gemfibrozil*.
- Losartan, 326, 351t
- Lovastatin, 315
- Low-density lipoprotein (LDL)  
cholesterol  
calculation of, 311  
CHD and, 41  
high-protein diets and, 53  
metformin and, 81  
rosiglitazone and, 93  
target/goal levels, 41, 258t, 312t, 313t  
treatment recommendations based on, 311-314, 313t  
goal levels, 41, 258t  
lowering, 311-314, 315t  
with bile acid sequestrants, 315  
with fibrates, 318  
with HMG-CoA reductase inhibitors, 45, 315-316, 315t  
with nicotinic acid, 315t  
in metabolic syndrome, 45  
pioglitazone and, 102, 105  
in Steno-2 Trial, 69

Macrovascular disease, 304-318  
 early damage from, 14-16  
 hypertension, 305-310  
 IGT and, 34  
 reduction with early diagnosis and treatment, 25-26  
 risk factors in, 304  
 specific diseases, 304

Macrovascular events, pioglitazone and (PROactive Study), 106

Macular edema, in diabetic retinopathy, 322. See also *Diabetic retinopathy*.

Malnutrition-related diabetes mellitus, 30t

Maturity-onset diabetes of the young, 35

Meal plan, 48

Medical evaluation (Diabetes Warranty Program), 40, 42-43

Medical Urethral System for Erection (MUSE), 335

Meglitinide. See *Repaglinide (Prandin)*.

MET. See *Metformin*.

Metabolic abnormalities in type 2 diabetes, 21-23, 24, 24, 63, 64  
 goals for treatment, 63, 65, 66t, 252t, 258t

Metabolic acidosis, in diabetic ketoacidosis, 287-288. See also *Diabetic ketoacidosis*.

Metabolic complications of T2D, 285-299. See also *Complications of diabetes*.

Metabolic control. See *Glycemic control*.

Metabolic goals of treatment, 63, 65, 66t, 252t, 258t, 304

Metabolic syndrome, 44-45  
 criteria for, 44t, 45t  
 first-line therapy for, 44-45  
 risk factors for, 40-41

Metaglip (glipizide/metformin), 78t, 83

Metformin (MET), 76t, 80-83  
 action mechanism, 80  
 in algorithm for treatment, 254  
 benefits of, 75, 80, 81  
 combination formulations, 77t-78t  
 with glipizide (Metaglip), 78t, 83  
 with glyburide (Glucovance), 78t, 82-83  
 with pioglitazone (Actoplus Met), 78t, 99, 100t-101t  
 with repaglinide (Prandin), 77t, 152  
 with rosiglitazone (Avandamet), 78t, 89-91, 90t  
 with sitagliptin (Janumet), 77t, 128-129  
 combination therapy, 80-83, 254  
 with acarbose, 143  
 with bromocriptine mesylate, 254  
 with colesevelam, 81, 254  
 with DPP-4 inhibitor, 254  
 with exenatide, 81, 203, 204-206, 205t, 207-208, 208-209, 209, 211, 212, 254  
 with glinides, 81, 149-151  
 with insulin/insulin preparations, 81, 191  
 with liraglutide, 214, 223-229, 224t-225t, 226t-227t, 228, 254  
 with nateglinide, 150-151, 150, 153-154, 154  
 with Novolog Mix, 191  
 with pramlintide, 238

Metformin (MET), combination therapy (*continued*)  
 with repaglinide, 149-151, 150  
 with rosiglitazone, 78t, 86-87, 89-91  
 with saxagliptin, 131-135, 134, 136t, 137  
 with SFUs, 78t, 80-81, 254  
 with sitagliptin, 121-122, 123, 126-127  
 with TDZs, 78t, 81, 254  
 triple-combination (TZD/repaglinide/MET), 117, 129, 151  
 contraindications/cautions, 82  
 dosage/titration, 75, 76t, 82  
 in combination therapy, 77t-78t, 82  
 effect on lipids, 81  
 formulations/trade names, 76t-79t  
 extended-release, 83  
 hypoglycemia and, 80  
 as initial therapy, 25, 75, 80, 253, 254  
 concurrent with lifestyle modifications, 75, 253, 254  
 monotherapy, 78  
 prescribing considerations, 82  
 side effects, 81-82  
 lactic acidosis, 81-82  
 minimization of, 81  
 trials and studies  
 ADOPT trial, 85-86, 86  
 Diabetes Prevention Program (DPP), 344t, 345-346  
 Steno-2 Trial, 69  
 UKPDS, 67-69  
 vs nateglinide, 153-155, 154  
 vs pioglitazone, 97  
 vs rosiglitazone, 85-86, 86  
 weight loss with, 81

Metoclopramide HCl, oral, 331

Metronidazole, 331

Microalbumin, measurement of, 261

Microalbuminuria  
 Candesartan and Lisinopril Microalbuminuria study, 309  
 in diabetic nephropathy, 323, 324-325, 326  
 glycemic threshold for developing, 326  
 macrovascular disease risk and, 304  
 in metabolic/dysmetabolic syndrome, 45, 45t  
 in Steno-2 Trial, 69, 70  
 treatment of, 44-45

Microaneurisms. See *Diabetic retinopathy*.

Micronase (glyburide). See *Glyburide*.

Micronized particles, in Glynase PresTab, 149

Microvascular complications of diabetes, 303, 318-336  
 prevention, as treatment goal, 253, 303-304, 318-319

Microvascular disease, 303, 318-336  
 reduction with glycemic control, 26, 66, 67t, 70, 303-304

Miglitol (Glyset), 76t, 144  
 action mechanism, 142, 144  
 combination therapy, 151  
 dosage, 76t, 144, 145t  
 PPG levels and, 144

- Miglitol (Glyset) (*continued*)  
 prescribing considerations, 144, 145t  
 side effects, 144
- Mineral supplementation, 56-57
- MiniMed Paradigm Real-Time System, 271t, 279-283
- Monitoring of glucose levels. See *Glucose monitoring*; *Glycemic control*.
- Monocyte chemoattractant protein-1 (MCP-1), 95
- Mononeuropathies, 327t, 330
- Monounsaturated fats, 52t, 54, 314t
- Morbidity and mortality  
 cardiovascular. See also *Cardiovascular risk*.  
 diabetes and, 40  
 of diabetes, 19  
 reduction with early detection and treatment, 19, 84, 318-319  
 fetal, gestational diabetes and, 35  
 macrovascular, pioglitazone and (PROactive Study), 106, 107, 108, 115  
 perinatal, postprandial hyperglycemia and, 65  
 postprandial hyperglycemia and, 65  
 in Steno-2 Trial, 70
- Mortality. See *Morbidity and mortality*.
- Muscular dystrophies, diabetes secondary to, 30t
- Myalgia, in diabetic ketoacidosis, 288t
- Myocardial infarction  
 $\beta$ -blockers and, 309  
 bromocriptine mesylate and, 161, 162  
 diabetes as risk equivalent, 40  
 incidence in newly diagnosed diabetics, 16  
 pioglitazone and, 114-115  
 rosiglitazone and, 114  
 in trials and studies  
 ACCORD trial, 71, 71  
 PROactive Study, 106, 107, 108  
 Steno-2 Trial, 70  
 UKPDS, 67, 67t
- Nateglinide (Starlix), 77t, 152-155  
 action mechanism, 152, 153  
 combination therapy, with metformin, 150-151, 150, 153-154, 154  
 dosage, 77t, 154-155  
 glycemic control with, 150, 153-154  
 indications for, 152  
 monotherapy, 152  
 in NAVIGATOR trial, 350  
 pharmacodynamics, 152-153  
 prescribing considerations, 154-155  
 side effects, 155  
 vs metformin, 153-155, 154  
 vs repaglinide, 150-151
- Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, 350
- National Center for Chronic Disease Prevention and Health Promotion, 357
- National Cholesterol Education Program (NCEP)  
 guidelines, 41-44  
 National Cholesterol Education Program (NCEP) (*continued*)  
 on diabetic dyslipidemia (stepped approach), 311-314  
 on LDL level, 41  
 on treatment/diagnosis of metabolic syndrome, 44  
 on treatment/prevention of CHD, 41
- National Diabetes Education Initiative (NDEI), 360
- National Diabetes Education Program (NDEP), 360
- National Diabetes Surveillance System, 17
- National Eye Institute (NEI), 360
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 352, 361
- National Kidney Foundation, 361
- Native Americans. See *American Indians*.
- Natural history of type 2 diabetes, 23-26, 24, 169
- Nausea and vomiting  
 with bromocriptine mesylate, 161  
 in diabetic ketoacidosis, 286, 288t  
 with exenatide, 207  
 with liraglutide, 229-230  
 with pramlintide, 246-247  
 as symptom of gastroparesis, 330
- NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial, 350
- NCEP. See *National Cholesterol Education Program*.
- NDEI (National Diabetes Education Initiative), 360
- NDEP (National Diabetes Education Program), 360
- NEI (National Eye Institute), 360
- Nephropathy. See *Diabetic nephropathy*.
- Nerve blocks, for painful diabetic neuropathies, 328, 329
- Neurogenic bladder, 324, 327t, 332
- Neurologic signs, in HHNS, 293-295
- Neurontin (gabapentin), 328, 329
- Neuropathy. See *Diabetic neuropathy*.
- Neutral protamine Hagedorn (insulin). See *NPH*.
- Niacin, in therapy for diabetic dyslipidemia, 315t
- Niaspan, 317
- Nicotinic acid  
 for diabetic dyslipidemia, 315t, 316t, 317, 318  
 secondary diabetes and, 30t
- NIDDK. See *National Institute of Diabetes and Digestive and Kidney Diseases*.
- Nifedipine, 310
- Non-insulin-dependent diabetes. See *Type 2 diabetes mellitus*.
- Nonpharmacologic treatment of type 2 diabetes, 47-62, 254. See also *Exercise*; *Nutrition*.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 328, 329
- Nova Max and Max Link monitoring systems, 268t
- Novo Nordisk, 298
- Novolin 70/30 (NPH-insulin), 171, 190  
 regimens for, 191  
 time course of action, 175t
- Novolog (aspart), 170, 190  
 for diabetic ketoacidosis, 291  
 time course of action, 172-173, 174t, 176

- Novolog Mix  
 Novolog Mix 70/30, 171, 186, 190  
 plus MET, 191  
 time course of action, 175t
- NPH, 171  
 for diabetic ketoacidosis, 291  
 disadvantages of, 187  
 dosage calculation for, 181t, 182t  
 hypoglycemia with, 185, 185  
 Novolin 70/30 (NPH-insulin), 192  
 regimens for, 177t  
 time course of action, 174t, 176  
 Treat-to-Target Study, 184-185, 184  
 vs detemir, 192-193
- NSAIDs, for painful peripheral neuropathies, 328, 329
- Nuclear factor kappa-binding activity (NFkappaB), 95
- Nutrition, 47-58. See also *Diet*; *Weight*.  
 alcohol intake, 52t, 57  
 assessment of food consumption/habits, 47  
 body weight considerations, 49-50, 50t  
 caloric intake, 51  
 carbohydrates in, 52t, 54-55  
 clinical trials involving, 343-346, 344t  
 consult with dietitian, 48  
 dietary recommendations, 51-57, 52t  
 exercise combined with, 44, 49, 63-64  
 fat intake, 52t, 53-54  
 fat substitutes, 56  
 fructose in, 55  
 goals of, 47  
 importance of, in therapeutic approach, 47  
 nutrient composition of diet, 51-57  
 poor, diabetic ketoacidosis and, 285  
 protein intake, 52t, 53  
 sucrose (sugar) intake, 52t, 55  
 suggested weights for adults, 49-50, 50t  
 sweeteners, nutritive/nonnutritive, 55-56  
 therapy with, 47-48  
 vitamin, mineral, and herb supplements, 52t, 56-57
- Obesity. See also *Diet*; *Nutrition*; *Weight*.  
 central  
 metabolic syndrome and, 40, 44t, 45t  
 as risk factor for cardiovascular disease, 40  
 as risk factor for type 2 diabetes, 22, 34, 37  
 clinical trials involving obese patients, 344t, 345-346, 347  
 diabetes screening and, 352  
 fat intake, dietary, and, 53-54  
 as insulin-resistant state, 195  
 obese type 2 diabetes patients  
 HEELA study (exenatide vs insulin glargine), 207  
 insulin dosage for, 186  
 intensive insulin therapy in, 186-187  
 morbidly obese, insulin requirements, 187
- Obesity, obese type 2 diabetes patients (*continued*)  
 pramlintide and, 245-246  
 SFUs and, 148  
 vs lean patients, 64  
 percentage of type 2 diabetics with, 49  
 as risk factor for diabetes, 13, 22, 24-25, 37  
 as risk factor for type 2 diabetes, 37  
 xenical and (XENDOS Trial), 344t, 347
- Olestra, 56
- Omega-3 fatty acids, in ORIGIN trial, 352
- OneTouch monitoring systems, 268t-269t
- Onglyza. See *Saxagliptin (Onglyza)*.
- Ophthalmologist, referral to, 322t
- Opium, tincture of, for diabetic diarrhea, 331
- Oral agents for type 2 diabetes, 75-168, 76t-79t. See also *specific agents and classes of agents*.  
 in algorithm for treatment, 254-255  
 choice of, 75-80  
 classes of agents, 76t-79t  
 alpha-glucosidase inhibitors, 76t, 142-145  
 bile acid sequestrants (colesevelam), 76t, 155-159, 317  
 dopamine receptor agonist (bromocriptine mesylate), 76t, 159-162  
 DPP-IV inhibitors, 76t, 116-142  
 glinides, 77t, 149-155  
 metformin (biguanide), 76t, 80-83  
 sulfonylureas, 77t, 146-149  
 thiazolidinediones (TZDs), 78t, 83-116  
 combination agents, 77t-78t  
 DPP-IV inhibitor/biguanide agent, 77t  
 sulfonylurea/biguanide agents, 78t  
 thiazolidinedione/biguanide agents, 78t, 89-91  
 thiazolidinedione/sulfonylurea agents, 78t, 91-93  
 combination therapy. See also *specific agents*.  
 in algorithm for treatment, 254-255  
 contraindications, general, 80  
 dosage recommendations, 76t-79t  
 as initial pharmacologic therapy, 75  
 concurrent with lifestyle changes, 75, 253  
 secondary failure of, 67, 72-73  
 as indication for insulin therapy, 169  
 self-monitoring of blood glucose recommendation with, 274
- Oral glucose tolerance test (OGTT)  
 in criteria for diabetes diagnosis, 38t  
 in diagnosis of diabetes, 38t, 39, 254  
 in diagnosis of IGT, 25
- ORIGIN (Outcome Reduction With an Initial Glargine Intervention) study, 350-352
- Orinase (tolbutamide), 77t, 146
- Orlistat (Xenical), in XENDOS Trial, 344t, 347
- Orthostatic hypotension. See *Hypotension, orthostatic*.
- Osteoporosis, calcium supplements and, 52t
- Otitis, 301t
- Outcome Reduction With an Initial Glargine Intervention (ORIGIN) study, 350-352

Pacific Islanders, 32, 37

PAI-1 (plasminogen activator inhibitor-1), 95, 105

Painful neuropathies, treatment/management of, 328-329, 329

Pancreatic disease, diabetes secondary to, 30t

Pancreatic enzymes, in treatment of diabetic diarrhea, 331

Pancreatic insulin secretion. *See Insulin secretion.*

Pancreatitis, acute, sitagliptin and, 128

Papaverine, 335

Paresthesias, 297

Pathophysiology of type 2 diabetes, 21-28

- as basis of pharmacologic therapy, 64-65
- disease phenotype, 21-23
- heterogeneity in, 23-24, 169-170
- metabolic abnormalities, 21-23, 24, 64
- natural history of diabetes, 23-26, 24

Patient education

- about hyperglycemia and retinopathy, 319
- about hypoglycemia, 178, 299
- with Diabetes Warranty Program, 42-43
- in nutrition and diet, 48
- in self-monitoring of blood glucose (SMBG), 55, 273

Patient motivation, 40, 60, 253

- with self-monitoring of blood glucose, 273

PCI. *See Percutaneous coronary intervention.*

Penile prostheses, 335-336

Percutaneous coronary intervention (PCI), in Steno-2 Trial, 70

Peripheral atherosclerotic artery disease, in Steno-2 Trial, 70

Peripheral vascular disease, 304. *See also Macrovascular disease.*

Peroxisome proliferator-activated receptors (PPARs), 83, 327

PGC. *See Plasma glucose concentration.*

Pharmacologic therapy for dyslipidemia, 315-318, 315t, 316t

Pharmacologic therapy for type 2 diabetes, 63-74. *See also specific drugs;*

- Treatment of type 2 diabetes.*
- as adjunct to diet and exercise, 63-64
- aggressive management, 63, 65-72
- algorithm for, 251-253, 254-255
- hyperglycemia, importance of controlling, 65, 66t
- insulin therapy, 169-198
- intensive therapy, 65-72
  - trials evaluating, 66-72
- oral agents, 63, 75-168
  - secondary failure of, 72-73
- overview of, 63-74
- pathophysiologic basis of, 64-65
- pramlintide therapy, 237-250
- when to consider/initiate, 63-64, 73

Phenotype B pattern, in diabetic dyslipidemia, 311

Phenotype of type 2 diabetes, 21-23

Phenoxybenzamine, for neurogenic bladder, 332

D-phenylalanine derivative (nateglinide), 152-155. *See also Nateglinide.*

Phenytol

- for painful neuropathies, 328
- secondary diabetes and, 30t

Pheochromocytoma, diabetes secondary to, 30t

Phosphate replacement

- in diabetic ketoacidosis, 290, 292
- in HHNS, 296

Phosphodiesterase-5 (PDE-5) inhibitors, 333-335, 334t

Photocoagulation, laser, 322-323

Physical activity. *See Exercise; Sedentary lifestyle.*

Physical examination, 42-43, 59

Pioglitazone (Actos), 78t, 97-110

- action mechanisms, 97
- boxed warning for, 111
- cardiovascular risk and, 99, 105, 111-115
  - PROactive Study, 105-108, 108, 115
- combination formulations, 78t, 99-102
  - with metformin (Actoplus Met), 78t, 98, 99, 100t-101t
  - with SFU-glimepiride (Duetact), 78t, 102, 103t, 104t
- combination therapy, 97-99, 98
  - PROactive Study, 105-108, 115
  - with saxagliptin, 137
  - with sitagliptin, 122-125, 124
- dosage, 78t
  - for combination agents, 78t
- effects/benefits of
  - cardiovascular risk, 99, 105
  - effect on lipid levels, 102-105
  - fat distribution, 105
  - glycemic control, 97-99, 98, 107-108, 109
    - with combination agents, 99, 100t-101t, 102, 103t, 104t
  - reduction in C-reactive protein, 105, 106
- monotherapy, 97, 98
- prescribing considerations, 109-110
  - Actoplus Met, 110
  - Duetact, 110
- safety and tolerability, 108
- side effects, 111-116
  - CHF and edema, 111-113, 113t
  - liver toxicity, 111
  - weight gain, 102
- trials and studies
  - ACT-NOW trial, 350
  - PROactive Study, 105-108, 115
  - TRIPOD, 347
  - vs metformin, 97, 98

Plasma glucose concentration (PGC)

- in assessment of treatment, 257
- as diagnostic criteria, 38t, 39
- home monitoring of. *See Self-monitoring of blood glucose (SMBG).*
- measuring, 257-259
- normal values, 38t
- postprandial, 65, 66t
- random testing, 39
- target/goal values, 257t
- testing for, 38-40, 38t

Plasminogen activator inhibitor-1 (PAI-1) antigen, 95, 105

PocketChem EZ monitoring system, 269t

- Polycystic ovary syndrome  
 as criterion for dysmetabolic syndrome X, 45t  
 diabetes secondary to, 31t  
 as risk factor for diabetes, 37
- Polydipsia  
 in diabetes mellitus, 37, 80  
 in diabetic ketoacidosis, 287  
 in HHNS, 293
- Polyphagia, as symptom of diabetes, 37
- Polysaturated fats, 52t, 54
- Polyuria  
 in diabetes mellitus, 37, 80  
 in diabetic ketoacidosis, 287
- Postprandial glucose (PPG), 29, 64-65, 251. See also *Hyperglycemia, postprandial*.  
 AACE guidelines for control of, 65, 66t  
 acarbose and, 143  
 alpha-glucosidase inhibitors and, 142-144  
 amylin and, 238-240, 240  
 gastric emptying and, 65, 240-241, 240  
 GLP agonists and, 199-200, 203  
 importance of controlling, 65  
 insulin control of, 240  
 liraglutide and, 214  
 miglitol and, 144  
 nateglinide and, 153, 154  
 normal levels, 243, 252t  
 pramlintide and, 242, 243, 244, 246  
 target levels, 66t, 252t, 258t, 304
- Postprandial hyperglycemia. See *Hyperglycemia, postprandial*.
- Potassium  
 antihypertensive agents and, 306t, 308  
 channels, 149, 152  
 dietary supplementation/restriction of, 56-57  
 replacement  
   in diabetic ketoacidosis, 290, 291  
   in HHNS, 296
- PPARs. See *Peroxisome proliferator-activated receptors*.
- PPG. See *Postprandial glucose*.
- Pramlintide therapy, 237-250. See also *Amylin*.  
 action mechanisms, 238-242, 240  
   centrally-mediated effects, 240, 240  
   food intake/satiety regulation, 239, 240, 241-242  
   gastric emptying, slowing of, 238, 240-241, 240  
   glucagon suppression, 239, 240, 241  
 clinical efficacy, 242-247  
   clinical practice study, 244, 246  
   glycemic control, long-term, 242-244, 245  
   postprandial glucose, 242, 243  
 combination therapy  
   with insulin, 237-238, 242, 243, 244, 245  
   with metformin, 238  
   with SFUs, 238
- Pramlintide therapy (*continued*)  
 dosing, 247-248  
   insulin dose and, 247-249  
   practical tips on, 248-249  
   timing of administration, 248-249  
 glucose homeostasis and, 238-240, 240  
 hypoglycemia with, 247  
 practical tips for patient, 248-249  
 side effects/adverse events, 246-247, 248  
 tolerability, 246-247  
 trade name (Symlin), 237  
 weight-loss effects, 242, 244, 245-246, 245
- Prandimet (repaglinide/metformin), 77t, 152
- Prandin. See *Repaglinide*.
- Pravastatin, 315, 316t
- Precision Xtra monitoring system, 269t
- Precose. See *Acarbose*.
- Prediabetes, 24  
 incidence of, 343  
 insulin secretion in, 22, 23
- Pregnancy. See also *Gestational diabetes mellitus*.  
 folic acid supplements in, 52t  
 risk assessment/diagnosis of GDM, 39-40  
 treatment choices in, 171, 254
- Prevalence of type 2 diabetes, 13-16, 14, 15, 32
- Prevention of diabetes, 343-354. See also *Early detection and management, benefits of*.  
 clinical trials  
   diabetes primary prevention trials, 343-350, 344t  
   ongoing, 350-352  
   reduced diabetes risk in other trials, 350, 351t  
 exercise and, 59  
 need for/importance of, 19, 303-304, 343, 350, 352  
 screening and, 352  
 summary of, 352
- Primary care provider  
 request for/review of SMBG data, 257, 262  
 routine medical evaluation, 40, 42-44, 59
- Primary prevention trials, diabetes  
 Da Qing IGT and Diabetes Study, 343-345, 344t  
 Diabetes Prevention Program (DPP), 344t, 345-346  
 Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) trial, 114, 344t, 348-350, 349  
 Finnish Diabetes Prevention Study (FDPS), 344t, 345  
 Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), 344t, 347  
 Troglitazone in the Prevention of Diabetes (TRIPOD) study, 344t, 346-347  
 Xenical in the Prevention of Diabetes Mellitus in Obese Subjects (XENDOS) Trial, 344t, 347
- PROactive Study, 105-108, 115
- Procoagulant state, 41, 44, 63, 251
- Prodigy monitoring systems, 269t
- Propoxyphene, in treatment of painful diabetic neuropathies, 328

PROspective pioglitAzone Clinical Trial in macroVacular Events.

See *PROactive Study*.

Prostaglandins, 335

Protein. See also *Diet; Nutrition*.

high-protein diets, LDL cholesterol and, 53

intake recommendations, 53

restriction, in therapy for diabetic nephropathy, 326-327

Proteinuria

antihypertensive drugs and, 306t

in diabetic nephropathy, 324, 325

*Pseudomonas aeruginosa*, in ear infections, 301t

Publications on diabetes, 355-361

Pump therapy (insulin), 177t, 188-189, 254

Pyelonephritis, 300t

Quality of life, impact of diabetes on, 285, 302

Questran, 317

Race/ethnicity

incidence of diabetes and, 18

prevalence of diabetes and, 13-14, 15, 32

risk for diabetes and, 23, 34, 37

screening for diabetes and, 352

Ramipril, 350

in DREAM Trial, 344t, 348-350, 349

in HOPE study, 351t

Recombinant DNA technology, insulin and analogues produced by, 192, 193

RECORD trial, 112

ReliOn Ultima monitoring system, 269t

Renal disease

antihypertensive agents, potential benefits of, 307t

glipizide and, 148

nateglinide and, 155

saxagliptin and, 141-142

sitagliptin and, 127

Renal function. See also *Diabetic nephropathy*.

excessive protein intake and, 53

monitoring, 141-142, 257

Renal insufficiency/failure, macrovascular disease and, 304

Renal transplant, 324

Repaglinide (Prandin), 77t, 149-152

action mechanism, 149

combination therapy

with acarbose or miglitol, 143, 151

fixed-dose combination (with MET; Prandimet), 77t, 152

with metformin, 149-151, 150

with TDZs, 149

triple-combination (TZD/repaglinide/MET), 129, 151

contraindications/cautions, 149

dosage, 77t, 151

glycemic control with, 150-151, 150

monotherapy, 149

prescribing considerations, 151

Repaglinide (Prandin) (*continued*)

side effects, 152

vs nateglinide, 150-151

Resources and publications on diabetes, 355-361

Respiratory complaints, in diabetic ketoacidosis, 287

RESULT trial, 88

Retinal detachment, 321

Retinopathy. See *Diabetic retinopathy*.

Rezulin (Troglitazone), 344t, 346-347

Rightest GM300 monitoring system, 269t

Risk factors, cardiovascular. See *Cardiovascular risk*.

Risk factors for diabetes, 13, 14, 25, 34, 37-38

clinical trials

ongoing, 350-352

primary prevention trials, 343-350, 344t

risk reduction in other trials, 350, 351t

Diabetes Prevention Program (DPP), 344t, 345-346

gestational diabetes mellitus as, 35

Rosiglitazone (Avandia), 78t, 84-97

action mechanism, 84

cardiovascular risk and, 111-115, 116

Black Box warning, 113

boxed warning, 111, 113

FDA advisory board on (2010), 116

combination formulations, 78t, 88-93

with glimepiride (Avandaryl), 78t, 91-93

with metformin (Avandamet), 78t, 89-91

combination therapy, 86-93

with insulin, 88

with liraglutide, 217-229, 218t-219t, 222, 228

with metformin, 78t, 86-87

in Avandamet, 78t, 89-91

with saxagliptin, 137

with SFUs, 86, 91-93

dosage, 78t, 95

for combination agents, 78t

effects/benefits of, 84-85, 93-95

$\beta$ -cell function, 85, 87, 93

cardiovascular risk, 85-86, 348-349

effects on lipids, 93

glycemic control, 84-85, 87-88, 88

Avandamet, 89-91, 90t

Avandaryl, 91, 94t

half-life, 84

monotherapy, 84-86, 86

prescribing considerations, 95-97

side effects, 87, 111-116

CHF and edema, 111-113, 113t

CVD and mortality risk, 85-86, 113-115, 116

liver toxicity, 111

weight gain/edema, 85

trials and studies

ACCORD trial, 113-114

ADOPT trial, 85-86, 86, 114

Rosiglitazone (Avandia), trials and studies (*continued*)

- DREAM trial, 114, 344t, 348-350, 349
- High A1C Study, 85
- RECORD trial, 112
- RESULT trial, 88
- TRIPOD and, 347
- VADT, 113-114
- vs glyburide, 84-86, 86
- vs metformin, 85-86, 86

Salt, dietary intake of, 52t, 305

Satiety, pramlintide therapy and, 241-242

Saturated fats, 52t, 54, 314t

Saxagliptin (Onglyza), 76t, 129-142

- actions of, 129-130
- adverse events, 141
- approval in United States, 116, 129
- $\beta$ -cell function and, 135
- combination therapy
  - with glyburide, 135-137, 138t-139t
  - with metformin, 131-135, 134, 136t, 137
  - with TZDs (pioglitazone or rosiglitazone), 137, 140
- contraindications/cautions, 141-142
- dosage, 76t, 141-142
- glycemic control with, 130-137, 142
- hypoglycemia and, 141, 142
- indications for, 129
- pharmacodynamics, 129
- prescribing considerations, 141-142
- renal impairment and, 141-142
- tolerability, 141
- trials and studies
  - combination trials, 131-137
  - long-term use, 137
  - monotherapy trials, 130-131, 131, 132-133

Screening

- for diabetes, 25, 37, 352
  - ADA/NIDDK position on, 352
  - cost-effectiveness of, 343, 352
  - Diabetes Warranty Program, 40, 42-43
  - gestational diabetes mellitus, 35, 39-40
  - risk factors prompting, 352
- for diabetic nephropathy, 324-325
- for IFG/IGT, 352
- for lipid abnormalities, 302t, 311

Secondary diabetes mellitus, 30t-31t

Sedentary lifestyle

- as risk factor for diabetes, 13, 22, 25, 34, 38, 59
- as risk factor for macrovascular disease, 304

Seizures, hypoglycemia and, 297

Self-monitoring of blood glucose (SMBG), 261-283, 266t-272t

- accuracy of, 262, 265
- advances in, 278-283
- advantages and disadvantages of, 264

Self-monitoring of blood glucose (SMBG) (*continued*)

- description of, 261-262
  - dietary adjustments and, 55, 57
  - exercise and, 60
  - hypoglycemia prevention and, 196, 263, 299
  - logbook, 275, 276-277
  - patient dosage adjustment via, 182, 182t, 275
    - algorithm form, 280-281
    - applying results to adjust insulin doses, 275-278
    - guidelines for, 282t
    - techniques for premeal hyperglycemia, 274t
  - patient education in techniques for, 55
  - patient education/motivation with, 273
  - for patients not taking insulin, 273-274, 274t
  - for patients taking insulin, 274-275
  - reasons for performing, 262-263
  - recommendation for all diabetes patients, 265
  - recommended frequency of, 273
  - record sheet, 276-277
  - specific systems for, 266t-272t
- Semmes Weinstein monofilaments, 336
- Sexual dysfunction, 327t, 332-336
- diagnosis of, 333
  - erectile dysfunction, defined, 332
  - medications causing, 333
    - antihypertensive agents, 306t
  - treatments, 333-336
    - intracavernosal injection, 335
    - Medical Urethral System for Erection (MUSE), 335
    - penile prostheses, 335-336
    - phosphodiesterase-5 (PDE-5) inhibitors, 333-335, 334t
    - testosterone, 333
    - vacuum constrictor devices, 335
    - yohimbine HCl, 333
- SFUs. See *Sulfonylureas*.
- Sickle cell trait, A1C and HbA<sub>1c</sub> testing, false lows with, 259
- Sidekick monitoring system, 269t
- Sildenafil (Viagra), 333-335, 334t
- Simvastatin, 315, 316t
- Sitagliptin (Januvia), 76t, 117-129
- adverse events, 127-128
    - acute pancreatitis, 128
  - approval in United States, 116, 117
  - $\beta$ -cell function with, 122, 123
  - body weight and, 127
  - in combination or add-on therapy, 121-127
    - with glimepiride, 125-126
    - with glipizide, 125
    - with insulin, 126
    - with metformin, 121-122, 123, 126-127
      - fixed-dose formulation (Janumet), 77t, 128-129
    - with SFU, 117
  - triple combination (with MET and TZD), 117, 129
  - with TZD (pioglitazone), 117, 122-125, 124

- Sitagliptin (Januvia)  
 contraindications/cautions, 128  
 dosing, 76t, 128  
   for Janumet, 77t, 129  
 durability of, 121  
 glycemic control with, 117-127, 118, 123, 142  
 hypoglycemia and, 120, 126-127, 128, 142  
 indications for, 117  
 as initial therapy, 117  
 pharmacology/pharmacokinetics, 117  
 prescribing considerations, 128  
 renal disease patients, use in, 127  
 side effects, 120-121  
 trials and studies  
   combination or add-on therapy, 121-127, 123, 124  
   monotherapy, long-term efficacy, 121  
   monotherapy trials, 117-121, 118  
 vs metformin, 120-121
- Sitagliptin/metformin (Janumet), 77t, 128-129
- Skin infections, 300t
- Skin reactions, 146
- Sleep disturbances, 302
- SMBG. See *Self-monitoring of blood glucose*.
- Smoking, macrovascular disease risk and, 304
- Sodium, dietary intake of, 52t, 305
- Starlix. See *Nateglinide*.
- Statins, 69, 155, 315t, 327
- Steatohepatitis (fatty liver), 111
- Steno-2 Trial, 69, 70
- STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 344t, 347
- Stress  
 in development of diabetic ketoacidosis, 285-286  
 test, prior to exercise program, 59, 61t
- Stroke  
 antihypertensive agents, potential benefits of, 307t  
 bromocriptine mesylate and, 161, 162  
 incidence in newly diagnosed diabetics, 16  
 in PROactive study, 106, 107, 108, 115  
 in Steno-2 Trial, 69, 70
- Studies. See *Trials and studies*.
- Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), 344t, 347
- Stupor, in diabetic ketoacidosis, 288t
- Sucrose (sugar) intake, 52t, 55
- Sugar (sucrose) intake, 52t, 55
- Sugar alcohols, 56
- Sulfonylureas, 77t, 146-149. See also *specific drugs*.  
 action mechanism, 146  
 alcohol intake and, 57, 147  
 in algorithm for treatment, 254  
 cautions and contraindications, 148, 149  
 combination agents  
   sulfonylurea/biguanide agents, 78t
- Sulfonylureas, combination agents (*continued*)  
 thiazolidinedione/sulfonylurea agents, 78t  
 combination therapy  
   with bromocriptine mesylate, 160-161  
   with exenatide, 203, 204-206, 205t, 209, 211, 212  
   with insulin, 147, 148  
   with liraglutide, 214  
   with metformin, 78t, 80-81, 254  
   with pioglitazone (Duetact), 78t, 102  
   with pramlintide, 238  
   with rosiglitazone, 78t, 86, 91-93  
   with saxagliptin, 135-137, 138t-139t  
   with sitagliptin, 117  
 dosage, 77t, 147  
 of combination agents, 78t  
 in elderly, 147  
 once-a-day, 146  
 drugs in this category, 77t, 146  
 efficacy, 146  
 first generation, 77t, 146  
   acetohehexamide (Dymelor), 77t, 146  
   chlorpropamide (Diabinese), 77t, 146  
   tolazamide (Tolinase), 77t, 146  
   tolbutamide (Orinase), 77t, 146  
 hypoglycemia and, 146, 147, 296  
 prescribing considerations, 147-148  
 second generation, 77t, 146, 148-149  
   advantages of, 146  
   glimepiride (Amaryl), 77t, 146, 148  
   glipizide (Glucotrol), 77t, 146, 148-149  
   glyburide (DiaBeta, Micronase, Glynase PresTab), 77t, 146, 149  
 side effects, 146-147  
 in UKPDS, 67-69
- Supplements, dietary, 52t, 56-57  
 in Steno-2 Trial, 69
- Sweeteners, nutritive/nonnutritive, 55-56
- Symlin. See *Pramlintide therapy*.
- Symptoms of diabetes/type 2 diabetes, 37
- Tachycardia, hypoglycemia and, 296
- Tadalafil (Cialis), 333-335, 334t
- Taking Control of Your Diabetes (TCOYD), 361
- Technosphere delivery system (for insulin), 170
- TENS (transcutaneous nerve stimulation), 328, 329
- Testosterone, 333
- Texas Diabetes Council, 253
- Thiazide diuretics, 306t, 307t, 310  
 impotence and, 333  
 secondary diabetes and, 30t  
 in Steno-2 Trial, 69
- Thiazolidinediones (TZDs), 78t, 83-116. See also *Pioglitazone*;  
*Rosiglitazone*.  
 action mechanisms, 83  
 in algorithm for treatment, 254

Thiazolidinediones (TZDs) (*continued*)  
 cardiovascular risk and, 111-115, 116  
 cardiovascular risk reduction with, 84  
 combination agents, 78t  
   triple-combination (TZD/repaglinide/MET), 117, 129, 151  
 combination therapy  
   with acarbose, 143  
   with exenatide, 203, 206, 208-209  
   with glinides, 149  
   with insulin, 88  
   with liraglutide, 214  
   with metformin, 78t, 81, 86-87, 89-91, 254  
   with repaglinide, 151  
   with SFUs, 78t, 86  
   with sitagliptin, 117  
 contraindications/cautions for, 111-113, 113t  
 dosage, 78t  
 early treatment with, benefits of, 84, 115-116  
 efficacy, 83-84  
 as first-line therapy, 25  
 insulin resistance, reduction with, 83-84  
 liver function, monitoring, 111  
 PPARs and, 83  
 side effects, 111-116  
   CHF and edema, 111-113, 113t  
   CVD and mortality risk, 113-115, 116  
   liver toxicity, 111  
 Thin (lean) patients, 64  
 Thrifty gene hypothesis, 18-19  
 Tolazamide (Tolinase), 77t, 146  
 Tolbutamide (Orinase), 77t, 146  
 Tolinase (tolazamide). See *Tolazamide*.  
 Tramadol (Ultram), 328, 329  
 Transcutaneous nerve stimulation (TENS), 328, 329  
 Treat-to-Target Study, 184-185, 184, 193  
 Treatment of type 2 diabetes. See also *Pharmacologic therapy for type 2 diabetes; specific treatments*.  
 aggressive, 289-290, 304  
   benefits of, 25-26  
 algorithm for, 251-253, 254-255  
 assessment of treatment regimen, 257-284  
 diet and nutrition in, 47-58  
 disease progression and, 25-26, 178, 188  
 early. See *Early detection and management, benefits of*.  
 GLP-1 analogues, 202-232  
 glycemic control with  
   importance of, 65, 238-240  
   intensive therapy for, 65-72  
   target levels/goals, 66t, 69-70, 72, 252t, 258t  
 goals of, 251, 258t  
   metabolic goals, 65, 66t, 252t, 258t, 304  
 initial, strategy for, 253, 254  
 insulin therapy, 169-198

Treatment of type 2 diabetes (*continued*)  
 intensive therapy, 65-72, 176-178, 304  
   trials evaluating, 66-72, 303-304  
 in lean vs obese patients, 64  
 with metabolic syndrome, 44-45  
 multipronged approach to, 237  
 nonpharmacologic, 47-62  
   pharmacologic concurrent with, 63-64, 253  
 oral agents, 75-168  
   pharmacologic, overview, 63-74  
   pramlintide therapy, 237-250  
   secondary failure of, 67, 68, 72-73  
   treatment modalities, 251  
 Trials and studies, 343-352, 344t, 351t. See also *specific trials*.  
 ACCORD trial, 69-70, 71, 71, 72, 113-114  
 ACT-NOW trial, 350  
 ADOPT, 85-86, 86, 114  
 ADVANCE trial, 69-70, 71-72  
 ALLHAT, 351t  
 Candesartan and Lisinopril Microalbuminuria study, 309  
 CAPP, 351t  
 CARDS, 316t  
 CARE, 316t  
 Cycloset Safety Trial, 161, 162  
 Da Qing IGT and Diabetes Study, 343-345, 344t  
 DCCT, 66, 253, 263-264, 303-304, 325  
 diabetes primary prevention trials, 343-350, 344t  
 DIAS, 316t  
 DPP, 344t, 345-346  
 DREAM trial, 114, 344t, 348-350, 349  
 Early Treatment Diabetic Retinopathy Study, 322-323  
 FDPS (Finnish Diabetes Prevention Study), 344t, 345  
 HEELA study, 207  
 Helsinki trial, 316t  
 High A1C Study, 85  
 HOPE trial, 308, 351t  
 HPS, 316t  
 intensive therapy, 65-72  
 LEAD (liraglutide), 216-229, 218t-219t, 220t-221t, 222, 224t-227t, 228  
 LIFE, 351t  
 NAVIGATOR trial, 350  
 ORIGIN study, 350-352  
 PROactive Study, 105-108, 115  
 RECORD, 112  
 RESULT trial, 88  
 Steno-2 Trial, 69, 70  
 STOP-NIDDM, 344t, 347  
 Treat-to-Target Study, 184-185, 184, 193  
 TRIPOD study, 344t, 346-347  
 UKPDS, 66-72, 66t, 67, 253, 263, 304, 308, 309, 325  
 VA-HIT, 316t  
 VADT, 70-71, 72, 113-114  
 VALUE, 351t  
 WOSCOPS, 351t  
 XENDOS trial, 344t, 347

Tricor. See *Fenofibrate*.

Tricyclic antidepressants, for painful neuropathies, 328, 329

Triglycerides

colesevelam and, 158

hypertriglyceridemia, 310, 318

lowering, 315t

with dietary reduction of saturated fats, 54

with fibric acid derivative, 318

in metabolic syndrome criteria, 44t

risk levels for adult diabetic patients, 37, 312t

target/goal levels, 258t, 312t

testing for, routine, 257

treatment of, in Steno-2 Trial, 69

TRIPOD (Troglitazone in the Prevention of Diabetes) study, 344t, 346-347

Troglitazone, 344t, 346-347

Troglitazone in the Prevention of Diabetes (TRIPOD) study, 344t, 346-347

True2Go monitoring system, 270t

TrueResult monitoring system, 270t

TrueTrack monitoring system, 270t

Twin studies, 21, 32

Tylenol, for painful diabetic neuropathies, 328, 329

Type 1 diabetes mellitus. See also *Diabetes mellitus*.

age of onset, 29, 30t, 35

amylin deficiency in, 238, 239

characteristics of, 29-32, 30t

diabetic ketoacidosis and, 286, 290

differences from type 2 diabetes, 32, 185-186

classification problems, 35-36

insulin-pump therapy for, 188-189

late-onset (LADA), 286, 290

pramlintide for, 238

Type 2 diabetes mellitus. See also *Diabetes mellitus*.

age of onset, 30t, 32

algorithm for treatment, 251-253, 254-255

asymptomatic, 32-33, 37

$\beta$ -cell failure in, 23, 238

characteristics of, 30t, 32-33

classification of, 30t, 32-33

problems with, 35-36

diagnosis, 37-46, 38t, 254

differences from type 1 diabetes, 32, 185-186

heterogeneous nature of, 23-24, 169-170

incidence, 16-19, 17, 18

metabolic abnormalities in, 21-23, 24, 63, 64

natural history, 23-26, 24

and progression of therapies, 169, 178, 188

pathophysiology, 21-23, 24

pharmacologic treatment overview, 63-74

prevalence, 13-16, 14, 15

resources and publications on, 355-361

signs and symptoms of, 32-33, 37

statistics on, 13-20

transition to, 21-23, 22-23, 24, 34

prevention or delay with treatment, 34, 343, 350, 352

undiagnosed, problems of, 14-16

TZDs. See *Thiazolidinediones*.

UKPDS. See *United Kingdom Prospective Diabetes Study*.

Ultralente, 187, 194

Ultram (tramadol), 328, 329

Undiagnosed diabetes, 13, 14-16, 37

HHNS in, 292

United Kingdom Prospective Diabetes Study (UKPDS), 66-72

cardiovascular risk reduction in, 67-69

diabetic retinopathy in, 16

drugs studied in, 308, 309

glycemic control benefits, 66-67, 67t, 68, 253, 263

microvascular disease reduction in, 66, 67t, 253, 304, 308

prevention/delay of complications in, 253, 303-304, 325

secondary failure in, 67, 68, 72-73

Uremia, 260, 288

Urinary tract infection

diabetes and, 300t, 302

diabetic nephropathy and, 324, 325

VA-HIT, 316t

Vacuum constrictor devices, in treatment of sexual dysfunction, 335

VADT. See *Veterans Affairs Diabetes Trial*.

Vagus nerve, 240

Valsartan, 326, 351t

VALUE (Valsartan Antihypertensive Long-Term Use Evaluation) trial, 351t

Vardenafil (Levitra), 333-335, 334t

Vascular disease, as risk factor for diabetes, 38. See also *Macrovascular disease*.

Veterans Affairs Diabetes Trial (VADT), 70-71, 72, 113-114

Viagra (sildenafil), 333-335, 334t

Victoza. See *Liraglutide (Victoza)*.

Vision loss. See *Diabetic retinopathy; Eyes*.

Vitamins/vitamin supplements, 56-57, 69, 325

Vitrectomy, in treatment of diabetic retinopathy, 323

VLDL particles, 310, 318

pioglitazone and, 105

Vulvovaginitis, 300t

WaveSense monitoring systems, 270t

Weight. See also *Obesity*.

in cardiovascular risk assessment, 257

diabetes screening and, 352

gain

with glimepiride, 223

with insulin therapy, 195-196, 237

intensive insulin therapy and, 186

with pioglitazone, 102

reduced with insulin detemir, 196

with rosiglitazone, 85, 223, 348

with sulfonylureas, 146

goal levels, 50t

ideal, calculation of, 51

Weight (*continued*)

- loss or neutrality, 44, 49-50
- benefits of, 49
- DPP-IV inhibitors and, 127, 142
- exenatide and, 205t, 206-207, 209-213, 209, 211, 213
- exercise and, 44, 59, 60
- GLP-1 therapy and, 201, 232
- guidelines, 49-50
- in hypertension treatment, 305
- liraglutide and, 216, 217, 221t, 223, 224t, 226t, 228-229
- means of achieving, 49
- metformin and, 81
- pramlintide and, 242, 244, 245-246, 245
- sitagliptin and, 127
- as symptom of diabetes, 37
- in treatment for metabolic syndrome, 44
- in type 1 diabetes, 29
- in type 2 diabetes, 32, 80
- macrovascular disease risk and, 305
- monitoring, 257
- normal, in some T2D patients, 50
- overweight patients, clinical trials involving, 344t, 345-346, 347
- as risk factor for diabetes/type 2 diabetes, 13, 22, 25, 34
- suggested weights for adults, 49-50, 50t

Welchol. See *Colesevelam*.

World Health Organization (WHO), diabetes criteria, 33t

WOSCOPS (West of Scotland Coronary Prevention Study), 351t

XENDOS (Xenical in the Prevention of Diabetes Mellitus in Obese Subjects) trial, 344t, 347

Xenical in the Prevention of Diabetes Mellitus in Obese Subjects (XENDOS) Trial, 344t, 347

Yeast infections, 37

Yohimbine HCl, 333